Investigation of ERK inhibition and Hedgehog signaling in myogenesis and cancer-associated muscle wasting by Au, Ernie Dennis
  
 
INVESTIGATION OF ERK INHIBITION AND HEDGEHOG 
SIGNALING IN MYOGENESIS AND CANCER-ASSOCIATED 
MUSCLE WASTING 
 
 
Ernie Dennis Au 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
In the Department of Biochemistry & Molecular Biology, 
Indiana University 
 
May 2018 
 ii 
Accepted by the Graduate Faculty of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
Doctoral Committee 
 
 
 
 
             
      Teresa A. Zimmers, Ph.D., Chair 
 
 
 
 
 
       
      David B. Burr, Ph.D. 
 
 
 
 
 
       
      Maureen A. Harrington, Ph.D. 
 
 
 
 
 
       
      Jingwu Xie, Ph.D. 
 
 
 
December 18, 2017 
 
 
 
 
 iii 
Dedication 
To my mother and father, for supporting and encouraging me in anything 
and everything I do. I am truly lucky to have you both as parents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
Acknowledgements 
I would like to thank my Ph.D. mentor, Dr. Teresa Zimmers. I am grateful 
that you welcomed me into your lab, and for the guidance and mentorship that 
you have given me throughout the course of my graduate career. I am forever 
indebted to you for the knowledge and experiences I have gained during my time 
there. 
I would also like to express my sincere gratitude to my committee 
members, Drs. David Burr, Maureen Harrington, and Jingwu Xie. You guys have 
always taken time out of your busy schedules for our meetings and provided 
excellent insight and feedback regarding my work. 
Lastly, I would like to extend my appreciation to past and current members 
of the Zimmers laboratory, especially Dr. Andrea Bonetto. Being able to learn 
from and discuss ideas with them has been invaluable. 
 
 
 
 
 
 
 
 
 
 
 v 
Ernie Dennis Au 
INVESTIGATION OF ERK INHIBITION AND HEDGEHOG SIGNALING IN 
MYOGENESIS AND CANCER-ASSOCIATED MUSCLE WASTING 
 
The ability to preserve, protect, or grow skeletal muscle would greatly 
benefit patients in health and disease. Understanding the molecular pathways 
that regulate muscle size is necessary to develop interventions. The extracellular 
signal-related kinase (ERK) and Hedgehog signaling pathways each play 
necessary roles in skeletal muscle development. The ERK pathway has been 
shown to both stimulate and inhibit muscle development at different stages, while 
Hedgehog signaling is vital for embryonic muscle development. Thus, these 
pathways represent prime targets for manipulation in diseases associated with 
muscle loss. 
In prior studies, cancer patients treated with the ERK inhibitor, 
Selumetinib, experienced significant gains in lean body mass. To study the 
mechanisms responsible, we tested the potential of Selumetinib to protect 
against muscle wasting in muscle cell cultures and in mice with experimental 
lung cancer. Selumetinib was able to induce hypertrophy of cultured muscle 
cells. In mice, we observed a reduction in tumor mass and in circulating 
mediators of muscle wasting including inflammatory cytokines. However, 
Selumetinib treatment did not prevent cancer-induced muscle loss. Together, 
these data suggest a diversity in the underlying molecular mechanisms and the 
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need for careful consideration when extrapolating results across different disease 
states, clinical trials, and model systems. 
In separate studies, we found that the Hedgehog pathway was increased 
in mice and patients with cancer-associated muscle wasting and inflammation. In 
a series of studies in muscle cell cultures, in genetically modified mice, and in 
mice bearing tumors, we found that inflammatory cytokines activated Hedgehog 
expression in muscle. Hedgehog signaling promoted the replication of muscle 
stem cells but reduced the expression of genes that specify mature muscle. 
Inhibiting Hedgehog signaling promoted muscle growth, while activating it caused 
muscle wasting. Furthermore, we identified unique properties of two proteins 
activated by Hedgehog, Gli1 and Gli2, where Gli1 appears to promote muscle 
stem cell proliferation and Gli2 mature muscle gene expression. These data 
implicate the Hedgehog pathway, GLI1 and GLI2 as targets for treatment of 
muscle wasting diseases. 
 
Teresa A. Zimmers, Ph.D., Chair 
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Chapter 1 
Introduction 
 
Skeletal muscle 
Skeletal muscle is one of the most highly plastic tissues in the human 
body. It comprises approximately 40% of total body mass, making it the most 
abundant tissue of the body 1. Skeletal muscle is the main organ system for 
locomotion. Mechanically, it functions to provide movement, generate force, and 
in the performance of daily activities. Metabolically, it provides amino acids and 
other substrates to other vital organs upon demand. The maintenance of skeletal 
muscle mass is critical for respiration, locomotion, metabolism, and hinges on a 
homeostatic balance between protein synthesis and degradation. I would argue 
that it is of utmost importance to have sufficient skeletal muscle to meet the 
metabolic requirements of healing or recovering, because muscle is where the 
body stores its reserves. In disease, the wasting of that muscle, which is normally 
necessary physiologically, becomes pathological because there is no healing of 
the wound or because the muscle has become epigenetically stuck in the 
wasting mode. This occurs during disease states such as acquired 
immunodeficiency syndrome, cardiac failure, and cancer 2-6. Moreover, it is 
essential to maintain skeletal muscle mass in order to preserve vitality and 
quality of life 7-10.  
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Skeletal muscle development and myogenesis 
During embryogenesis, skeletal muscle develops from the somites in the 
paraxial mesoderm 11. Several factors play critical regulatory roles during this 
process and are indispensable for muscle formation. Two of the major regulatory 
genes for muscle progenitors cells are Pax3 and Pax7 12. These transcription 
factors are necessary for the survival, specification, and progression into 
myogenesis of progenitor cells 13. Other key components are the muscle specific 
genes myogenic regulatory factor 4 (MRF4), myogenic factor 5 (Myf5), and 
myogenic differentiation 1 (MyoD) (Figure 1-1). Upregulation of these factors 
allows for muscle cell differentiation, and are required for skeletal muscle 
formation 14-17. Two other important proteins responsible for the activation of 
muscle specific genes are myogenin and myocyte enhancer factor 2 (MEF2) 18-20. 
Along with several signaling molecules, these factors coordinate a complex 
network that determines when and where skeletal muscles will form and develop. 
 
Figure 1-1. Myogenic differentiation. The Pax3 and Pax7 transcription factors control the 
myogenic specification of progenitor cells. They directly target and induce expression of Myf5 and 
MyoD for myogenic determination. This is followed by an upregulation of myogenin and MRF4 
and induction of myogenic differentiation. Pax3/7 positive cells that do not express myogenic 
regulatory factors remain as muscle satellite cells, which can undergo myogenesis as a result of 
future stimuli. Figure is taken from Dumont et al., 2015 21. 
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Skeletal muscle in health and disease 
The importance of skeletal muscle is undisputable, and its loss extremely 
debilitating. Muscle wasting reduces quality of life, decreases response/tolerance 
to therapy, and increases morbidity and mortality. The loss of skeletal muscle 
can occur during acute trauma, systemic disease, or chronic illness. Trauma, 
such as volumetric muscle loss, can lead to prolonged or permanent functional 
deficits 22,23. With systemic disease such as cancer-induced cachexia, preventing 
the loss of muscle mass has been shown to prolong life in animal models 24,25. In 
chronic diseases that can often be incurable, preventing muscle loss may 
improve patient’s quality of life. It has been shown that in chronic obstructive 
pulmonary disease, muscle mass and strength correlate directly with mortality 
26,27. As such, it is imperative to investigate new targets for therapeutic 
intervention of muscle wasting diseases. 
 
Current therapies 
Treatment options to preserve muscle mass or prevent wasting are 
limited, and some are not feasible with certain patients. Exercise is a validated 
form of therapy and has shown efficacy in animal models of muscle atrophy, but 
its use excludes patients who are bed-ridden or critically ill 28,29. Increasing 
nutrient uptake has also been explored as a potential avenue of treatment. In 
cancer cachexia, clinical trials using various appetite stimulants have shown 
some efficacy with regards to muscle mass and improving quality of life 30-33. One 
of the main features of cachexia is a chronic state of systemic inflammation. As 
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such, other strategies aim to inhibit the inflammatory cytokines that are known to 
cause wasting. Antagonists to Activin and Myostatin have been shown to protect 
against atrophy and increase muscle and body mass 25,34-36. Hormones such as 
ghrelin and insulin-like growth factor 1 have also been investigated for the 
treatment of muscle wasting in various systemic and chronic disease states 37-40. 
In patients, ghrelin administration has been shown to have positive effects on 
body weight 41,42. However, these therapeutic strategies are controversial as they 
increase the levels of various growth hormones, and may inadvertently increase 
the risk or growth of cancer or neoplasias 43,44. 
 There is unlikely to be one universal treatment for muscle wasting in any 
disease state, and multimodal approaches are likely needed. Thus, it is 
necessary to explore other molecular pathways that play a role in the regulation 
of skeletal muscle mass in the hopes of exploiting their therapeutic potential. 
 
Extracellular signal-regulated kinase in skeletal muscle 
 The activity of extracellular signal-regulated kinase (ERK) can be 
stimulated by a variety of growth factors and mitogens 45,46. These factors 
activate receptors, in conjunction with other adaptors, to initiate a signaling 
cascade through small GTP-binding proteins. These binding proteins activate the 
main components of the pathway which is composed of Raf, MEK1/2 and ERK. 
Once activated, ERK can phosphorylate a variety of transcription factors and 
results in a modulation of target gene expression (Figure 1-2). 
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Figure 1-2. ERK signaling pathway. Signaling is initiated by the binding of factors to receptors. 
This results in the activation of a downstream signal transduction. Figure is taken from Gibney et 
al., 2013 47. 
 
In skeletal muscle myoblasts, ERK has been shown to play stage-
dependent roles. ERK activation in satellite cells has been shown to promote 
their proliferation while suppressing differentiation, by preventing withdrawal from 
the cell cycle 48-51. This activity can be induced by a variety of factors including 
fibroblast growth factor and insulin-like growth factor 52-55. As it promotes 
proliferation, ERK activity is decreased during the initial phases of myogenic 
differentiation. However, as differentiation proceeds, ERK is again activated 56-58, 
with the ERK2 isoform shown to be essential for formation and fusion of murine 
myoblasts 59,60. While the exact mechanisms by which ERK exerts both inhibitory 
and stimulatory roles during differentiation remain unclear, it has been suggested 
that its function is dependent on its cellular localization 61.  
 
Hedgehog signaling in skeletal muscle 
 The Sonic hedgehog (Shh) signaling cascade has been studied 
extensively for its role in development. The pathway consists of ligands, the 
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Patched (Ptch) receptor, and the Smoothened (Smo) receptor. The effectors of 
this signaling pathway are the downstream Gli family of transcriptions factors, 
which regulate target gene expression (Figure 1-3). Hedgehog is another 
pathway that plays an important role in skeletal muscle. During development, 
Shh is instrumental in skeletal muscle patterning and fiber distribution 62. In 
addition, Shh has been shown to directly initiate the myogenic program in muscle 
progenitor cells in the developing limb bud. This is accomplished through a Gli 
mediated activation of Myf5 63. Moreover, Shh signaling is also responsible for 
regulating the migration of progenitor cells that will give rise to various skeletal 
muscles 64. While the pathways role in muscle development has been well 
described, its role in adult skeletal muscle remains unclear. 
 
 
Figure 1-3. Hedgehog signaling pathway. In the absence of a ligand, the activity of Smo is 
repressed by Ptch (left). Binding of a ligand to the Ptch receptor relieves its repression on Smo, 
thus allowing for activation of the downstream Gli transcription factors (right). Figure is taken from 
Martin et al., 2010 65. 
  
 
 
Ligand
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Summary 
The ability to preserve, protect, or grow skeletal muscle would greatly 
benefit patients across several disease states. Muscle-preserving therapies could 
improve quality of life, prolong life, and increase tolerance to treatments 66-68. 
Given their roles in the development of skeletal muscle and myogenesis, the 
ERK and Shh pathways represent prime candidates for further investigation as 
potential therapeutic targets for diseases associated with muscle wasting. 
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Chapter 2 
Investigating MEK inhibition as a treatment for cancer-induced cachexia 
 
Introduction 
 It is estimated that roughly 50% of patients who die of cancer, die with 
cachexia, and some 30% die as a result of the cachexia 69. This uncontrolled loss 
cannot be fully reversed with nutritional support, leading to progressive 
impairment of motor function and immobility 4,70. Muscle wasting reduces quality 
of life, decreases response to therapy, and contributes directly to mortality. Low 
muscle mass also increases chemotherapy toxicity, while chemotherapy can 
cause muscle wasting and contribute to cachexia directly 71-74. Currently there 
are no approved therapies for cancer cachexia, although treatment approaches 
include promoting appetite and absorption of food, anti-inflammatory drugs, and 
pro-anabolic approaches 75,76. As such, it is imperative to explore additional 
means to combat this devastating syndrome. 
 Several underlying mechanisms have been implicated in directly 
contributing to cachexia. Cachexia has been referred to as an energy imbalance 
disease, where intake is decreased and expenditure is increased. However, even 
with a measured energy intake, the imbalance remains 77. The loss of muscle 
mass is largely due to abnormalities in protein metabolism, with a constant cycle 
in which degradation outweighs synthesis. This was shown to be caused partly 
by increased activity of the ubiquitin-proteasome pathway or autophagy 78,79. 
Degradation of myofibrillar proteins results directly in muscle weakness, fatigue, 
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and atrophy. Signaling pathways responsible for the turnover of skeletal muscle 
proteins can be induced by a multitude of inflammatory cytokines, both tumor- 
and host-derived. Cachectic mediators include tumor necrosis factor alpha 
(TNF), Myostatin, Activin, members of the transforming growth factor beta 
(TGF-) superfamily of ligands, and Interleukin-6 (IL-6) 80-84. IL-6 binds IL-6 
receptor and GP130 to activate signal transduction cascades of the downstream 
ERK, Akt, and STAT3 pathways 85. It has been shown by others, as well as in our 
lab, that IL-6 alone is sufficient to induce muscle wasting both in vitro and in vivo 
86-88. This is largely through activation of STAT3 88 downstream of GP130 and 
JAK. Inhibition of IL-6, IL-6 receptor, or STAT3 have all been shown to reduce 
cachexia in experimental systems 89-92. Moreover, therapies targeted at inhibiting 
IL-6 have shown promise in human lung cancer cachexia 93.  
In addition to IL-6, a variety of mitogenic and inflammatory stimuli can 
activate the Mitogen activated protein kinase (MAPK)/ERK pathway. These 
include various cytokines and growth factors which signal through tyrosine kinase 
receptors 94. MEK1/2 activation of ERK influences survival, growth, proliferation, 
and inflammatory processes 95,96. The MEK pathway can also be activated by 
oncogenic Ras. As such, the pathway has been a target of interest for potential 
anti-cancer therapies 97. The selective small molecule MEK1/2 inhibitor, 
Selumetinib, decreases phosphorylation and activation of ERK1/2 98 and shows 
efficacy in various cancer models of the lung, skin, ovary and liver 99-102. 
A phase II clinical trial of Selumetinib showed weight gain in patients with 
biliary cancer, a condition that is typically associated with severe wasting 103. 
 18 
Retrospective re-analysis of those data showed that patients receiving 
Selumetinib experienced significant gains in skeletal muscle, while those on 
standard therapy experienced muscle loss 103,104. In skeletal muscle, inhibition of 
the ERK pathway, via a dominant negative form of Raf or a pharmacological 
inhibitor, resulted in robust myotube hypertrophy 105. ERK inhibition has also 
been shown to derepress myogenic differentiation caused by cardiotrophin-1, a 
member of the IL-6 family of cytokines 106. During early stage skeletal muscle cell 
differentiation, myogenin expression becomes upregulated. This increase in 
myogenin mRNA levels is accompanied by a concomitant decrease in ERK1/2 
phosphorylation, and pharmacological inhibition of ERK1/2 significantly increases 
myogenin mRNA 107. Moreover, in a C26 colon carcinoma mouse model of 
cancer cachexia, ERK inhibition was shown to be protective against muscle 
wasting 108,109. 
Given the encouraging results of Selumetinib in patients and of ERK 
inhibition in animal models, we sought to investigate the effect of Selumetinib in a 
Lewis lung carcinoma (LLC) model of cancer-induced cachexia 110. Based on the 
results of the retrospective analysis, and the published literature on the effects of 
ERK inhibition on skeletal muscle, we hypothesized, given its reported 
hypertrophic effects, that inhibition of ERK would protect against cachexia. We 
found that MEK inhibition lead to in vitro hypertrophy, in vivo tumor killing and 
inhibition of IL-6 in mice, but showed no evidence of anti-cachexia effects 111. 
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Materials and methods 
Cell cultures 
LLC cells were maintained at low confluency at 37C in a humidified 
atmosphere of 5% CO2. The cells were grown in culture medium consisting of 
Dulbecco’s Modified Eagle Medium (DMEM), 10 % fetal bovine serum (FBS), 
100 u/mL penicillin, and 100 mg/mL streptomycin. In preparation for injection, 
cells were trypsinized, counted, and resuspended in phosphate buffered saline 
(PBS). 
Murine C2C12 myoblasts (ATCC) were maintained at low confluency in a 
humidified atmosphere of 5% CO2. Culture medium consisted of DMEM with 10% 
FBS, 100 u/mL penicillin, and 100 mg/mL streptomycin. To induce differentiation, 
confluent cells were switched to differentiation medium consisting of DMEM with 
2% horse serum, 100 u/mL penicillin, and 100 mg/mL streptomycin. Myoblasts 
were differentiated for four days into mature myotubes. At this time, either 10 nM 
Selumetinib or vehicle was added to the media and the myotubes cultured for an 
additional two days. 
In the experiment using plasma from LLC tumor bearing mice, C2C12 
cells were again differentiated for four days. The media was then replaced with 
media consisting of DMEM with 2% plasma from control or LLC tumor bearing 
mice, 100 u/mL penicillin, and 100 mg/mL streptomycin. These groups were 
further divided into groups either receiving vehicle or 10 nM Selumetinib. The 
myotubes were then cultured for an additional two days prior to downstream 
analyses. 
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Animals 
 All experimental animal protocols were approved by and used in 
compliance with the Indiana University School of Medicine Institutional Animal 
Care and Use Committee. Eight week old male C57BL/6J mice were obtained 
from The Jackson Laboratory and allowed to acclimate for one week prior to the 
start of the experiment. Mice were maintained on a regular light-dark cycle and 
allowed free access to food and water throughout the duration of the experiment. 
The following experimental groups were used for this study: Control + vehicle 
(n=6), LLC + Vehicle (n=8), and LLC + Selumetinib (n=8). Mice designated in the 
tumor bearing groups were subcutaneously injected with 1x106 LLC cells into the 
interscapular region on day 0, with treatments beginning 24 hours later. 
Selumetinib (Selleck Chemical) was solubilized in a vehicle of 0.5% 
methylcellulose and 0.2% Tween 80. Vehicle or 25 mg/kg of Selumetinib was 
administered twice daily by gavage to the designated groups 112-114. Body 
weights of all mice were recorded daily. The study concluded on day 17 when 
some mice reached the criteria for a humane endpoint, at which point all mice 
were euthanized under isoflurane general anesthesia. Skeletal muscles, tumors, 
and organs were dissected free and weighed. Tissues were snap frozen in liquid 
nitrogen while some were preserved using alternative methods based on the 
downstream analysis (described later), and stored at -80C. The weights of 
individual tissues are expressed as a percentage of the animal’s initial body 
weight (IBW) in order to normalize for small difference in starting body size. 
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Immunofluorescence and immunohistochemistry 
 C2C12 myotube cultures were fixed and permeabilized in an ice cold 
solution of acetone:methanol (1:1) at -20C for 20 minutes. Following fixation, the 
cells were rehydrated in PBS for 10 minutes at room temperature. Cells were 
then blocked in an 8% bovine serum albumin (BSA) solution for one hour before 
being incubated with a primary antibody against myosin heavy chain (MyHC) (MF 
20, Developmental Studies Hybridoma Bank), at a dilution of 1:200 in PBS, 
overnight at 4C with gentle agitation. The following day, cells were washed with 
PBS and incubated with an AlexaFluor 488-labeled anti-mouse IgG (R37120, Life 
Technologies) secondary antibody, at a dilution of 1:1,000 in PBS, for one hour 
at room temperature and protected from light. Nuclei were stained with DAPI and 
images were captured on an Axio Observer.Z1 (Zeiss). Myotube diameters were 
measured using ImageJ analysis software (Wayne Rasband, U.S. National 
Institutes of Health). Only fully formed myotubes with the majority in the field of 
view were measured. 
 Skeletal muscle fiber cross-sectional area (CSA) was measured using the 
tibialis anterior muscle. Following necropsy, tibialis anterior muscles were 
mounted on cork discs with Tissue-Plus Optimal Cutting Temperature (Fisher 
Scientific) and frozen in 2-methlybutane cooled in liquid nitrogen before being 
stored at -80C. Frozen sections were cut using a Leica CM1860 cryostat (Leica 
Microsystems Inc.). Slides of muscle sections were fixed in ice cold 100% 
acetone at -20C for 10 minutes, and rehydrated in PBS for 10 minutes. Sections 
were then blocked in an 8% BSA solution for one hour at room temperature 
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before being incubated with a primary antibody against dystrophin (VP-D508, 
Vector Laboratories), at a dilution of 1:60 in PBS, overnight at 4C. The following 
day, sections were washed with PBS and incubated with an AlexaFluor 594-
labeled anti-mouse IgG (R37121, Life Technologies) secondary antibody, at a 
dilution of 1:1,000 in PBS, for one hour at room temperature. Images were 
captured with an Axio Observer.Z1 and muscle fiber cross-sectional area was 
measured using an ImageJ macro developed by Dr. Richard Lieber 115. 
 For immunohistochemical analysis, tumor tissue was fixed in formal and 
embedded in paraffin before sectioning. Sections were first deparaffinized in 
xylene and ethanol. Antigen retrieval was accomplished by boiling slides in a 
10mM sodium citrate buffer at pH 6.0 for 10 minutes. The sections were then 
cooled at room temperature for 30 minutes before being blocked in an 8% BSA 
solution for 1 hour. A primary antibody against IL-6 (ab6672, Abcam), at a 
dilution of 1:1,000 in PBS, or normal rabbit IgG (Santa Cruz Biotechnology) was 
then incubated on the sections overnight at 4C. Antibody detection was done 
using the ImmPRESS HFP Anti-Rabbit IgG (Peroxidase) Polymer Detection kit 
and ImmPACT DAB Peroxidase (HRP) Substrate as per manufacturer’s 
instructions (Vector Laboratories). 
Western blotting 
 Skeletal muscle and tumor tissue were homogenized on ice in lysis buffer 
consisting of 25 nM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), protease and phosphatase 
inhibitor cocktail tablets (Roche). Tissue homogenates were then separated by 
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centrifuging at 14,000 rpm for 15 minutes at 4C. Following centrifugation, the 
supernatant was collected and stored at -80C. Protein concentration of the 
supernatant was measured using the Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific) as per the manufacturer’s instructions. Equal amounts of 
protein extracts (30 g) were denatured at 95C for 5 minutes in sample loading 
buffer consisting of 125 mM Tris pH 6.8, 4% SDS, 20% glycerol, 1% bromphenol 
blue, and 200 mM dithiothreitol (DTT). Samples were resolved on Tris-Glycine 
gels before being transferred to nitrocellulose membranes (Bio-Rad 
Laboratories). Membranes were blocked in SEA BLOCK (Thermo Fisher 
Scientific) blocking buffer for one hour at room temperature and then incubated 
at 4C overnight with gentle agitation with primary antibodies against: IL-6 
(AB1839, EMD Millipore), α-Tubulin (12G10, Developmental Studies Hybridoma 
Bank), Phospho-p44/42 MAPK (ERK1/2) , p44/42 MAPK (ERK1/2), and GAPDH 
(4370, 4695, 5174, Cell Signaling Technology). All primary antibodies were used 
at a dilution of 1:1,000 in SEA BLOCK. Following primary antibody incubation, 
membranes were washed in a solution of PBS and 0.2% Tween 20. Anti-mouse 
IgG DyLight 680 and anti-rabbit IgG DyLight 800 secondary antibodies (5470, 
5151, Cell Signaling Technology)., at a dilution of 1:10,000 in SEA BLOCK, were 
incubated on the membranes for one hour at room temperature with gentle 
agitation. Following a final wash, membranes were imaged and quantified using 
an ODYSSEY CLx Infrared Imaging System and software (LI-COR). 
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IL-6 immunoassay 
 Whole blood was collected from all mice during euthanasia, via cardiac 
puncture, into BD Vacutainer Plastic Blood Collection Tubes with K2EDTA (Fisher 
Scientific) and kept on ice. Plasma was separated by centrifugation at 3,500 rpm 
for 15 minutes at 4C and stored at -80C. IL-6 was detected by a mouse 
magnetic 1-plex custom kit as per the manufacturer’s instructions (Life 
Technologies). All samples were run in duplicate and detected using the 
MAGPIX (Luminex) platform. 
Data analysis 
 Statistical significance was determined by an unpaired t test for 
experiments containing only two groups. In experiments that contained three or 
more groups, statistical significance was determined by one-way analysis of 
variance (ANOVA) followed by Tukey’s multiple comparisons test. A p-value 
greater than 0.05 was considered to be statistically significant.  
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Results 
Selumetinib induced hypertrophy in C2C12 myotubes 
We first looked to see what the in vitro effects of Selumetinib would be on 
myotubes. C2C12 myoblasts proliferate as mononuclear cells when maintained 
at low confluency. These cells can be induced to differentiate, when switched to 
a low serum medium, and form multinucleated myotubes. This system has 
previously been used in our lab to assess either hypertrophic or atrophic effects 
of conditioned medium, plasma, recombinant proteins, or small molecules 86,87. In 
this experiment, C2C12 myoblasts were differentiated into myotubes for four 
days. The cultures were then incubated with either vehicle or 10 nM Selumetinib 
for an additional 2 days, with a media change after the initial 24 hours (Figure 2-
1). 
 
Figure 2-1. In vitro C2C12 model of Selumetinib treatment. Graphical representation of 
experimental design with C2C12 cells. Myoblasts were differentiated into myotubes for four days 
before receiving the indicated treatment for an additional two days. 
 
Western blotting analysis showed that Selumetinib significantly reduced 
phosphorylation of ERK1/2 at both 1 and 10 nM (Figure 2-2A). Accompanying 
the reduced ERK1/2 activation, was a significant increase in myotube diameter 
Day 1
C2C12 myoblasts
Differentiation
Day 7
- Fix 
- Stain
- Image
- Measure
Day 5
- Drug addition
Selumetinib
C2C12 myotubes
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(+15.24%) compared to control (Figure 2-2B). This effect was seen with 10 nM 
Selumetinib treatment, but not at the 1 nM concentration. Higher doses were 
tested and found to be toxic (data not shown). These data suggest that inhibition 
of ERK1/2 phosphorylation induces C2C12 myotube hypertrophy. 
 
Figure 2-2. Treatment of myotubes with Selumetinib results in hypertrophy. C2C12 
myoblasts were differentiated into myotubes before treatment with varying concentrations of 
Selumetinib. A: Western blotting analysis of C2C12 myotubes shows that 1 and 10 nM of 
Selumetinib reduced phosphorylated ERK1/2 (normalized to total ERK1/2). Data are expressed 
as the means  standard deviation (SD). Statistical significance was determined by one-way 
ANOVA. *p<0.05, **p<0.01 versus Control. B: Representative images of myotubes treated with 
10 nM Selumetinib or vehicle. Myotube Cultures were stained for MyHC. Treatment with 10 nM 
Selumetinib induced myotube hypertrophy (+15.24%). All conditions were performed in triplicate 
and the data are expressed as the means  standard error of the means (SEM). Statistical 
significance was determined by one-way ANOVA. *p<0.05 versus Control.  
 
Selumetinib inhibited phosphorylation of ERK1/2 in skeletal muscle 
 With hypertrophic effects on myotubes observed in vitro, we next sought 
to investigate the in vivo effect of Selumetinib on skeletal muscle in the context of 
cancer-induced cachexia. To test this, we injected C57BL/6J mice with LLC cells, 
a validated and traditional model of experimental cancer cachexia, while control 
mice received a PBS injection. Treatment with 25 mg/kg Selumetinib or vehicle 
control was given twice daily by gavage and began 24 hours after tumor cell 
A
α-Tubulin 55 kDa
pERK1/2 42/44 kDa
Total ERK1/2 42/44 kDa
Control 1 nM 10 nM
B
Control 10 nM
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inoculation. Body weights were recorded at baseline and daily throughout the 
course of the experiment. No changes in body weight or body composition were 
observed amongst the groups (data not shown). On day 17 of the experiment, 
tumor bearing mice receiving vehicle treatment began to meet the criteria for 
euthanasia due to humane reasons. At this point, mice in all groups were 
euthanized and necropsies performed to harvest various skeletal muscles and 
organs. In order to determine if there was an on-target effect of Selumetinib on 
skeletal muscle, western blotting analysis for phospho-ERK1/2 was performed on 
lysates from quadriceps muscles. We found that systemic administration of 
Selumetinib was able to inhibit phosphorylation of ERK1/2 in the skeletal muscle 
(Figure 2-3A). Compared to vehicle treated controls and LLC tumor bearing mice, 
Selumetinib treatment in tumor bearing mice reduced phospho-ERK1/2 73.31% 
and 74.03% respectively (Figure 2-3B). Levels of total ERK1/2 protein were not 
statistically different between any group. This data suggested that Selumetinib 
had an on-target effect in skeletal muscle. 
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Figure 2-3. In vivo inhibition of ERK1/2 phosphorylation in skeletal muscle. LLC cells were 
injected subcutaneously into C57BL/6J mice. Tumor bearing mice received either vehicle or 
25mg/kg Selumetinib. A: Western blotting images show that Selumetinib treatment in LLC tumor 
bearing mice inhibited phosphorylation of ERK1/2 (normalized to total ERK1/2) in the skeletal 
muscle, while levels of total ERK1/2 were unchanged. B: Quantification of western blotting 
images. Data are expressed as the means  SD. Statistical significance was determined by one-
way ANOVA. ***p<0.001 versus Control + Vehicle, ###p<0.001 versus LLC + Vehicle. 
 
IL-6 expression was reduced in the blood and tumor tissue, but not muscle 
IL-6 is an inflammatory cytokine that has been extensively studied as a 
causal factor in cancer-induced cachexia. It has been reported that Selumetinib 
blocks the production of IL-6 116. Based on this we next looked at whether 
Selumetinib could inhibit IL-6 production in this model. We first looked at IL-6 
levels in the skeletal muscle. Western blotting analysis of quadriceps muscles 
showed no differences among any of the groups (Figure 2-4). 
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Figure 2-4. Selumetinib did not reduce IL-6 levels in muscle. Western blotting analysis shows 
that quadriceps IL-6 levels were not changed in cachexia or with Selumetinib treatment. Data are 
expressed as the means  SD. 
 
We next looked at levels in the tumor tissue. With western blotting 
analysis, we found that in tumor bearing mice treated with Selumetinib, IL-6 was 
significantly decreased as compared to the vehicle treated group (Figure 2-5A). 
This finding was further supported by immunohistochemical staining for IL-6 in 
sections of tumor tissue (Figure 2-5B).  
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Figure 2-5. Selumetinib reduced IL-6 in the tumor. Tumor bearing mice receiving Selumetinib 
exhibited a significant reduction of tumor IL-6 compared to vehicle treated tumor bearers. A: 
Western blotting analysis of tumor lysates show that Selumetinib blocked the production of IL-6. 
Data are expressed as the means  SD. Statistical significance was determined by unpaired t 
test. *p<0.05 versus LLC + Vehicle. B: Representative images of immunohistochemistry staining 
for IL-6 in tumor sections. 
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Lastly, we looked at circulating levels of IL-6. At the time of necropsy, 
whole blood was collected from all mice and the plasma extracted. Tumor 
bearing mice treated with vehicle showed a significant increase in the levels of 
IL-6 compared to vehicle treated control mice. Selumetinib treatment resulted in 
a drastic decrease of IL-6 levels compared to vehicle treated tumor bearers 
(Figure 2-6). Furthermore, the levels in the Selumetinib treated tumor bearers 
were not significantly different from non-tumor bearing controls. Taken together, 
these data show that treatment with Selumetinib reduced both tumor and 
circulating levels of IL-6, but not those in the skeletal muscle. 
 
Figure 2-6. Selumetinib reduced circulating IL-6. Plasma extracted from the mice was used for 
an IL-6 immunoassay. Tumor bearing mice treated with vehicle had a significant increase in IL-6 
compared to control mice. Selumetinib greatly reduced IL-6 in tumor bearing mice. Data are 
expressed as the means  SD. Statistical significance was determined by one-way ANOVA. 
**p<0.01 versus Control + Vehicle, ##p<0.01 versus LLC + Vehicle. 
 
Selumetinib reduced tumor size but did not protect against muscle wasting 
or fat loss 
 We next looked to determine if Selumetinib was able to prevent muscle 
and fat wasting. Compared to the vehicle treated tumor bearers, we observed a 
reduction in the final tumor mass (Figure 2-7A). Given the significant decrease in 
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tumor size, we expected muscle wasting to be attenuated. In this model, the 
severity of cachexia generally correlates with the level of tumor burden. However, 
in all the skeletal muscle tissues analyzed, both Selumetinib and vehicle treated 
tumor bearers exhibited a similar level of wasting (Figure 2-7A). Further analysis 
of the muscle cross-sectional area showed the same pattern of wasting as those 
observed with the muscle weights (Figure 2-7B). These data suggest that 
Selumetinib does not protect against cancer-induced cachexia. 
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Figure 2-7. Selumetinib does not protect against cancer-induced cachexia. Weights of 
tumor, various muscles, and adipose tissues were weigh at the time of necropsy. Tissue weights 
are normalized to the IBW (except tumor). A: Tumor mass was significantly reduced with 
Selumetinib treatment. Similar wasting in the quadriceps, gastrocnemius, and tibialis anterior 
muscles were observed in both vehicle and Selumetinib treated tumor bearing mice. Loss of 
epididymal fat mass appears to be greater in the Selumetinib treated group. Data are expressed 
as the means  SD. Statistical significance was determined by one-way ANOVA. *p<0.05, 
**p<0.01 versus Control + Vehicle. B: Representative images of muscle fiber cross-sectional area 
analysis from tibialis anterior muscles. Data are expressed as the means  SD. 
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Selumetinib does not protect against LLC plasma-induced myotube 
atrophy 
 While we observed a decrease in both tumor mass and circulating levels 
of IL-6, Selumetinib treatment did not display any protective effects against 
muscle or fat wasting. This led us to question if there were other cachexia drivers 
present in the LLC model that could not be modulated by Selumetinib. In order to 
investigate this question, we went back to an in vitro model using C2C12 
myotubes. In this experiment, C2C12 myotubes were simultaneously treated with 
plasma from control or LLC tumor bearing mice, and either vehicle or 10 nM 
Selumetinib (Figure 2-8).  
 
Figure 2-8. LLC plasma and Selumetinib model. Graphical representation of experimental 
design. C2C12 myoblasts were differentiated into myotube for four days. The myotubes were 
then incubated for an additional two days with the designated treatments. 
 
As with our prior in vitro experiment (Figure 2-2B), 10 nM Selumetinib was able 
to reproducibly induce myotube hypertrophy. Treatment of myotubes with plasma 
from LLC tumor bearing mice induced atrophy, which was not prevented with co-
treatment of 10 nM Selumetinib (Figure 2-9A). Further analysis showed that 
ERK1/2 inhibition resulted in a significant increase in the number of nuclei per 
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fiber (Figure 2-9B). Western blotting analysis confirmed the inhibition of ERK1/2 
phosphorylation in myotubes treated with Selumetinib (Figure 2-9C). Taken 
together, these data suggest that there are other factors driving the cachectic 
phenotype observed in the LLC model. Although Selumetinib was able to reduce 
levels on IL-6 in the tumor and blood, it does not appear to be able to modulate 
other potential drivers, resulting in the disconnect between the hypertrophic 
phenotype observed in vitro, and the lack of protection against cancer-induced 
cachexia in vivo. 
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Figure 2-9. Inhibition of ERK1/2 phosphorylation does not prevent LLC plasma-induce 
atrophy. C2C12 cells were differentiated for four days before being incubated for an additional 
two days with the indicated treatment. The experimental groups are as follows: Control, Control + 
10 nM Selumetinib, LLC Plasma, LLC Plasma + 10 nM Selumetinib. A: Representative images 
and quantification of myotube diameter. Myotubes treated with Selumetinib showed hypertrophy, 
while those treated with plasma from tumor bearing mice atrophied. Co-treatment of LLC plasma 
with Selumetinib was unable to block the atrophy. All conditions were performed in triplicate and 
the data are expressed as the means  SEM. Statistical significance was determined by one-way 
ANOVA. *p<0.05, **p<0.01, ***p<0.001 versus Control Plasma only. B: Representative images 
and quantification of nuclei per fiber. Myotubes treated with Selumetinib showed a significant 
increase in the number of nuclei per fiber, while this was decreased with LLC plasma. Again, 
Selumetinib was unable to attenuate the reduction in nuclei per fiber induced by plasma from LLC 
tumor bearing mice. All conditions were performed in triplicate and the data are expressed as the 
means  SEM. Statistical significance was determined by one-way ANOVA. ***p<0.001 versus 
Control Plasma only. C: Western blotting analysis of myotubes treated with control or LLC 
plasma, with or without 10 nM Selumetinib. Phosphorylation of ERK1/2 (normalized to total 
ERK1/2) was significantly reduced in both groups receiving Selumetinib. Total ERK1/2 protein 
levels were unchanged amongst the groups. Data are expressed as the means  SD. Statistical 
significance was determined by one-way ANOVA. ****p<0.0001 versus Control Plasma only. 
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Discussion 
 In this study, we show that unlike the results reported in patients with 
biliary cancers, mice with lung cancer do not exhibit a preservation of lean 
muscle mass with Selumetinib treatment, despite a reduction in tumor size. 
These results were unexpected, as we found that Selumetinib was able to 
increase C2C12 fiber size in vitro, suggestive of a potential pro-anabolic effect on 
skeletal muscle. Moreover, we observed an increase in the number of nuclei per 
fiber, suggesting that inhibition of ERK1/2 phosphorylation may have increased 
the differentiation or fusion potential of myoblasts. However, despite reducing 
ERK1/2 phosphorylation in the skeletal muscle of LLC tumor bearing mice, 
Selumetinib did not provide any protective or hypertrophic effects. This was 
especially surprising due to the substantial inhibition of tumor growth that we 
observed. In general, tumor mass directly correlates to the extent of wasting, 
therefore a diminished tumor burden should theoretically reduce the severity of 
cachexia. The disconnect seen here suggests that Selumetinib, in this context, 
may actually inadvertently inhibit pro-anabolic pathways or enhance pro-
cachectic pathways in the skeletal muscle of LLC tumor bearing mice. Lastly, the 
pro-cachectic pathways must be independent of IL-6. In this study, both 
circulating and tumor levels of IL-6 were greatly reduced with Selumetinib 
treatment. This was further supported due to the inability of Selumetinib to block 
LLC plasma-induced C2C12 myotube atrophy. The data suggest that another, or 
multiple other, inflammatory cytokines or circulating factors are the main driver/s 
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of skeletal muscle wasting the in the LLC model, and Selumetinib was unable to 
attenuate it/them. 
 It is possible that the effects of Selumetinib on tumor growth and the 
preservation of muscle mass are disease specific, as Selumetinib treatment is 
associated with increased lean body mass in patients with biliary cancers 104. In 
murine models of experimental cancer cachexia, Selumetinib shows efficacy in 
the C26 colon adenoma model. Biliary, colon, and lung cancers might all induce 
muscle wasting through a variety of different effectors. In some studies which 
utilize the C26 model, ERK inhibition is shown to have no effect on tumor mass, 
while protecting against cancer-induced cachexia 108,117. However, another study 
using the same model reports a preservation of skeletal muscle and total and 
lean body weight, but the tumor mass is significantly less than the vehicle treated 
tumor bearers 109. It should be noted though that these studies all use a different 
inhibitor and mice from a different genetic background than those used in this 
study. 
 The MEK pathway may also play different and context dependent roles in 
human versus murine cancer cachexia. In the phase II clinical trial of patients 
with biliary cancers, 52% of the patients that were treated with Selumetinib 
experienced a decrease in the target lesion size, similar to what we observed in 
our study. This could offer an explanation as to the gain in total body mass of 
patients treated with Selumetinib, as opposed to those patients receiving 
standard therapy. The increase in muscle mass could be a result of a reduced 
tumor burden, and not a direct effect on the skeletal muscles themselves. The 
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authors hypothesize that the anabolic effects of Selumetinib is likely due to the 
inhibition of cytokine secretion. However, we observed a significant decrease in 
both tumor tissue and circulating levels of IL-6, with no preservation of skeletal 
muscle mass. 
 Lastly, the lack of muscle preservation we observed could be due to the 
differential regulation and requirements of the MEK pathway during myogenesis. 
While skeletal muscle satellite cells were not investigated in this study, it is 
possible that the constant inhibition of the MEK pathway led to a decrease in 
proliferation and subsequent depletion of the satellite cell pool. Published 
literature shows that ERK signaling is both stimulatory and inhibitory in the 
context of muscle differentiation. It has been shown the ERK1/2 activation is 
required for the proliferation and self-renewal of satellite cells 118,119. However, 
this activation was not shown to be necessary for fusion of the expression of 
various muscle specific genes 120. Additionally, ERK2 is necessary for the 
formation of mature myotubes. In C2C12 myoblasts, siRNA mediated knockdown 
of ERK2 resulted in an inability to fuse and form multinucleated myotubes 59. 
There is also potential crosstalk from other pathways that should be considered. 
The Akt pathway, which is a positive regulator of muscle mass, is activated 
during differentiation of myotubes and leads to inhibition of the MEK pathway 105. 
Conversely, effectors such as leukemia inhibitory factor, part of the IL-6 family of 
ligands, inhibit myogenic differentiation through ERK1/2 phosphorylation and 
activation 121. Further work in C2C12 cells show that in the first 24 hours post 
induction of differentiation, ERK1/2 activation represses myogenic inhibition. 
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Inhibition of MEK1 in the latter stages of differentiation show similar effects of 
defective myotube formation 122. These data show that myogenesis is a 
coordination of low MEK1 activity in the initial stages of differentiation, and high 
pathway activity thereafter. As such, while administration of Selumetinib inhibited 
tumor growth in LLC bearing mice, achieving the desired anabolic effects appear 
to be much more complicated. 
 Due to the apparent differential activation of ERK1/2 during myogenesis, it 
would seem that constant inhibition of the pathway may be detrimental to skeletal 
muscle mass. The prior studies mentioned had the ability to control the myogenic 
stages at which the pathway was inhibited or activated. This approach would be 
challenging to accomplish in vivo, although a potential alternative would be to 
administer the Selumetinib treatment intermittently. This method of dosing would 
allow for times of pathway activation, as opposed to being in a relatively constant 
state of inhibition. Based upon the published literature, allowing for cycles of 
activation and inhibition could potentially produce the desired stimulatory effects 
that are needed for skeletal muscle hypertrophy. Future investigations will be 
necessary in order to determine a proper dosing regimen required to exploit the 
therapeutic potential of ERK inhibition as a treatment against cancer-induced 
cachexia, and the effects of such dosing on tumor growth. 
 Taken together, this study suggests the need to consider the differential 
regulation of not only the MEK and IL-6 pathways, but other pathways that have 
been implicated in the muscle wasting of cancer cachexia. Moreover, the data 
point to deeply distinct drug-response phenotypes in conventional models of 
 41 
experimental cancer cachexia. This suggests a diversity in the underlying cellular 
and molecular mechanisms and a need for careful consideration when 
extrapolating results across different disease states, clinical trials, and model 
systems. 
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Chapter 3 
Investigating the role of the Hedgehog signaling pathway in adult skeletal 
muscle homeostasis 
 
Introduction 
 The loss of skeletal muscle can stem from a variety of causes. These can 
include severe trauma, volumetric muscle loss 22,123, chronic diseases including 
AIDS, cardiac failure, and cancer 3, and degenerative diseases like the muscular 
dystrophies 124,125. Significant losses of skeletal muscle can reduce quality of life, 
cause permanent disabilities, decrease response or tolerance to therapies, and 
contribute directly to morbidity and mortality. 
 Our lab has found the Hedgehog (Hh) pathway to be dysregulated in the 
skeletal muscle of cachectic tumor bearing mice. In addition, we have substantial 
data implicating the pathway as a causal factor in wasting. From a clinical 
standpoint, GDC-0449 (Vismodegib) and LDE225 (Sonidegib), which inhibit 
pathway activity through inhibition of Smo, are currently FDA-approved for the 
treatment of advanced basal cell carcinoma. Given this, it would be 
advantageous to explore other potential applications and clinical uses for these 
drugs. Investigating new pathways to target for the treatment or aid in skeletal 
muscle preservation, growth, or regeneration would benefit patients across 
several disease states. However, in order to safely and effectively take 
advantage of any drug, we must first understand the role of the Hh pathway in 
maintaining skeletal muscle homeostasis, which is currently unclear. 
 43 
 The Hh pathway is of vital importance during the embryonic development 
of insects, some invertebrates, and vertebrates 126-128. In vertebrates, three 
homologs have been identified, Shh, Indian hedgehog, and Desert hedgehog 129. 
The core of the Hh signaling pathway revolves around four main components, 
ligands, the Ptch receptor, the Smo receptor, and the Gli family of transcription 
factors. During the absence of a ligand, Ptch normally acts to constitutively 
repress Hh signaling by inhibiting the activity of the Smo receptor. Upon binding 
of a ligand, Ptch repression of Smo is relieved, allowing for Smo activation of a 
cytoplasmic signal transduction cascade. This leads to the activation and nuclear 
translocation of Gli transcription factors and modulation of target gene expression 
130-132. 
 The importance of Shh signaling during embryonic development has been 
well described. It plays an essential role in patterning of both chick and mouse 
embryos 133,134. During the development of skeletal muscle, the Hh pathway 
plays a role in regulating the expression of myogenic regulatory factors such as 
Myf5 and MyoD 134-137. However, in the context of muscle myogenesis, the 
published data on the role of Shh signaling are conflicting and there is a lack of 
investigation of the pathways role in adult skeletal muscle. It has been shown 
that treating primary chick myoblasts and murine C2 cells, with an active N-
terminal peptide of Shh, results in the promotion of both proliferation and 
differentiation 138. Similar results were observed in another study using primary 
chick myoblasts, where exogenous Shh increases myotube formation and 
bromodeoxyuridine incorporation, a marker for cellular proliferation 139. 
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Conversely, treatment of murine C2C12 and primary satellite cells with Shh 
retained the cells in a mononucleated and undifferentiated state. Concomitant 
treatment with cyclopamine, a Smo inhibitor, was able to reverse these effects 
and allow for formation of multinucleated myotubes 140. 
 While some investigation on the pathways role in myogenesis has been 
done, the role of the Hh pathway in the maintenance of skeletal muscle mass has 
yet to be examined. Given our findings of elevated Hh signaling in atrophic 
muscle, we hypothesized that the Hh pathway acts as a negative regulator of 
adult skeletal muscle mass. Therefore, we sought to explore the skeletal muscle 
phenotype of mice with elevated Hh pathway activity. To approach this question, 
we utilized several in vitro and in vivo models. In vitro, Hh pathway activity was 
modulated through pharmacological means, as well as with siRNA mediated 
knockdown of Hh pathway members. From these experiments, we observed 
alterations in both myotube diameter and the number of nuclei per fiber, 
suggesting that the pathway alters the dynamics of differentiation. In vivo, 
systemic administration of a Hh pathway agonist in wild-type (WT) C57BL/6J 
mice resulted in a muscle wasting phenotype. In addition, we also used a 
transgenic model of increased Hh pathway activity. These mice were 
heterozygous for Ptch1, which normally functions as the endogenous inhibitor of 
the pathway 141. As such, it would be expected that these mice would have 
elevated Hh pathway activity 142. We found these mice to have a 
hypotrophic/atrophic skeletal muscle phenotype, with additional evidence of 
reduced myogenesis and muscle function. 
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Materials and methods 
Cell cultures 
 Murine C2C12 cells (ATCC) were grown in DMEM with 10% FBS, 100 
U/mL penicillin, and 100 mg/mL streptomycin. The cells were maintained at low 
confluency at 37°C in a humidified atmosphere of 5% CO2. To induce 
differentiation, confluent cells were switched to a low serum medium containing 
DMEM supplemented with 2% horse serum, 100 U/mL penicillin, and 100 mg/mL 
streptomycin. The pharmacologic compounds GDC-0449, LDE225, GANT61, or 
SAG (Selleck Chemicals) were diluted to the indicated concentration in 
differentiation medium. 
For siRNA-mediated knockdown, a commercially available siRNA targeted 
towards Ptch1 and a negative control were purchased (Table 1). C2C12 
myoblasts were cultured in growth medium as above. Transfection of the 
designated siRNA was performed using Lipofectamine 3000 as per the 
manufacturer’s instructions (Thermo Fisher Scientific). Knockdown of Ptch1 was 
confirmed via qPCR at 24 hours post transfection.  
Animals 
 All experimental animal protocols were approved by and used in 
compliance with the Indiana University School of Medicine Institutional Animal 
Care and Use Committee. Purmorphamine (Selleck Chemicals) was 
administered at a dose of 30 mg/kg in a solution of 30% polyethylene glycol via 
intraperitoneal injection, to eight week old male C57BL/6J mice (The Jackson 
Laboratory). Ptch1+/lacZ mice and WT littermates at various ages were obtained 
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from The Jackson Laboratory. All mice were maintained on a regular light-dark 
cycle and allowed free access to food and water at all times. 
 Skeletal muscle function was assessed using the four-limb grip strength 
assay with a digital force gauge (Extech). This assay was performed by allowing 
the mice to grip a gauge with all four paws before being pulled from the base of 
the tail until the mouse could no longer hang on, thus generating a measurement 
of peak force 143. 
 Body composition analysis was measured using EchoMRI-500 Whole 
Body Magnetic Resonance Analyzer (EchoMRI) 144. This equipment allows for 
live animal analysis without the use of anesthetics. The EchoMRI analyzer can 
quantify total body lean and fat mass. 
 At the conclusion of the experiment, euthanasia was performed under 
isoflurane general anesthesia. Skeletal muscles were identified, dissected free, 
and weighed. Portions of the muscle tissue were immediately snap frozen in 
liquid nitrogen before being stored at -80°C. This tissue was later used for protein 
and RNA extraction. Skeletal muscle designated for histomorphometric analysis 
was frozen in liquid nitrogen cooled 2-methylbutane before being stored at -80°C 
for future sectioning. The weights of skeletal muscle tissues are expressed as a 
percentage of total body weight (TBW) in order to normalize for any variations in 
body size. 
Immunofluorescence 
 C2C12 myotubes were fixed and permeabilized in an ice cold 
acetone:methanol (1:1) solution for 20 minutes at -20°C. The cells were then 
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rehydrated with PBS at room temperature for 10 minutes before being blocked in 
an 8% BSA solution for one hour. Primary antibody against MyHC, at a dilution of 
1:200 in PBS, (MF 20, Developmental Studies Hybridoma Bank) was incubated 
overnight at 4°C with gentle agitation. The following day, cultures were washed 
with PBS before being incubated with an AlexaFluor 488-labeled anti-mouse IgG 
secondary antibody (R37120, Life Technologies), at a dilution of 1:1,000 in PBS, 
for one hour at room temperature and protected from light. Following rounds of 
PBS washes, nuclei were stained with DAPI and images were captured on an 
Axio Observer.Z1 (Zeiss). Myotube diameters were measured using ImageJ 
analysis software (Wayne Rasband, U.S. National Institutes of Health). Only fully 
formed myotubes with the majority in the field of view were measured. 
 For analysis of skeletal muscle fiber cross-sectional area, tibialis anterior 
muscles were mounted on cork discs with Optimal Cutting Temperature 
compound and frozen as mentioned above. Frozen sections were cut using a 
Leica CM1860 Cryostat (Leica Microsystems Inc.). The sections were then fixed 
in 100% acetone for 10 minutes at -20°C, rehydrated with PBS for 10 minutes at 
room temperature, and blocked for one hour with an 8% BSA solution. Primary 
antibody against dystrophin (VP-D508, Vector Laboratories), at a dilution of 1:60 
in PBS, was incubated on the slides overnight at 4°C. Following washes with 
PBS, the slides were incubated with an AlexaFluor 594-labeled anti-mouse IgG 
secondary antibody (R37121, Life technologies), at a dilution of 1:1,000 in PBS, 
for one hour at room temperature and protected from light. Images were captured 
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using an Axio Observer.Z1 (Zeiss) and muscle fiber cross-sectional area 
quantified using a macro installed on ImageJ analysis software 115. 
 Primary myofibers were isolated from the flexor digitorum brevis (FDB) 
muscle and fixed as previously described 145. Primary antibody against Pax7 
(Pax7, Developmental Studies Hybridoma Bank) was incubated on the cultures 
overnight at 4°C. Following PBS washes, detection was performed using an 
AlexaFluor 594-labeled anti-mouse IgG1 secondary antibody (A-21125, Life 
Technologies) at a dilution of 1:1,000 in PBS. The Nuclei were stained with DAPI 
and images were captured on an Axio Observer.Z1 (Zeiss).  
Western blotting 
 Frozen quadriceps muscles were homogenized on ice in tissue lysis buffer 
consisting of 25 nM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS, and protease and phosphatase inhibitor cocktail 
tablets (Roche). Whole tissue homogenates were centrifuged at 14,000 rpm at 
4°C for 15 minutes and the supernatant collected and stored at -80°C. The 
concentration of protein extracts was determined as previously mentioned in 
Chapter 2, and equal amounts of protein were denatured at 95°C for 5 minutes in 
loading buffer containing 125 mM Tris pH 6.8, 4% SDS, 20% glycerol, 1% 
bromphenol blue, and 200 mM dithiothreitol. Protein samples were resolved on 
Tris-Glycine gels before being transferred to nitrocellulose membranes (Bio-Rad 
Laboratories). The membranes were then blocked in Odyssey Blocking Buffer 
(LI-COR) for one hour at room temperature while shaking. The membranes were 
incubated overnight at 4°C with gentle agitation with primary antibodies directed 
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against: Phospho-Akt Substrate, Phospho-Akt, Akt, Phospho-AMPK Substrate, 
Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif, Phospho-ATM/ATR Substrate, 
Phospho-CDK Substrate, eNOS, Phospho-p44/42 MAPK (ERK1/2) , p44/42 
MAPK (ERK1/2), Phospho-MAPK Substrate, nNOS, Phospho-PKA Substrate, 
Phospho-PKC Substrate, Phospho-Stat3, Stat3, and Ubiquitin (9614, 4060, 
9272, 5759, 2981, 6966, 9477, 32027, 4370, 4695, 2325, 4231, 9624, 6967, 
9145, 4904, 3933, Cell Signaling Technology), and -Tubulin (12G10, 
Developmental Studies Hybridoma Bank). All primary antibodies were used at a 
dilution of 1:1,000 in SEA BLOCK. Anti-mouse IgG DyLight 680 and Anti-rabbit 
IgG DyLight 800 fluorescent dye secondary antibodies at a dilution of 1:10,000 in 
SEA BLOCK (5470, 5151, Cell Signaling Technology) were used for detection, 
and incubated on the membranes for one hour at room temperature while 
shaking and protected from light. Membranes were imaged and quantified using 
the ODYSSEY CLx Infrared Imaging System and software (LI-COR). 
Gene expression analysis 
 Total RNA was extracted from cells and whole tissue using the QIAGEN 
miRNeasy kit (QIAGEN Inc.) and cDNA generated using the Verso cDNA 
Synthesis kit (Thermo Fisher Scientific) as per the manufacturer’s instructions. 
Relative mRNA expression levels of the genes of interest were measured using 
TaqMan Assay based probes (Thermo Fisher Scientific) on a LightCycler 96 
(Roche). A complete list of the probes used in this study can be found on Table 
3-1 below. 
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For RNA-Sequencing, total RNA was first evaluated for quantity and 
quality using an Agilent Bioanalyzer (Agilent). For quality purposes, only samples 
with a RIN number of 7 or higher were used. For library preparation, a starting 
amount of 1000 ng of total RNA was used. PolyA mRNA capture of total RNA 
was performed using the Dynabeads mRNA DIRECT Micro Kit (Ambion). 
Preparation of the cDNA library included enzymatic fragmentation, hybridization 
and ligation of adaptors, reverse transcription, size-selection, and amplification 
with barcode primers, following the Ion Total RNA-Seq Kit as per the 
manufacturer’s instructions (Life Technologies). The resulting barcoded libraries 
were quantified and the qualities assessed using an Agilent Bioanalyzer. Eight 
microliters of 100 pM pooled libraries were then applied to an Ion Sphere 
Particles (ISP) template preparation, and amplification done using an Ion 
OneTouch 2 (Life Technologies), followed by ISP loading onto a PI chip and 
sequencing performed on an Ion Proton semiconductor (Life Technologies). 
Each PI chip allowed for approximately 140 million ISP templates, thus 
generating approximately 80-100 million usable reads, up to 10-15 Gb. 
Data analysis 
Statistical significance was determined by unpaired t-test for experiments 
containing two groups. For experiments containing groups of three or more, 
statistical significance was determined by one-way ANOVA followed by Tukey’s 
multiple comparisons test. For experiments with two independent variables, a 
two-way ANOVA was used. A p-value less than 0.05 was considered to be 
statistically significant. 
 51 
Table 3-1. 
siRNA   
Target Catalog # Manufacturer 
Negative 4390846 Thermo Fisher Scientific 
Ptch1 s72339 Thermo Fisher Scientific 
   
Probes   
Target Catalog # Manufacturer 
Fbxo32 Mm00499523_m1  Thermo Fisher Scientific 
Gli1 Mm00494654_m1  Thermo Fisher Scientific 
Gli2 Mm01293117_m1 Thermo Fisher Scientific 
Gli3 Mm00492337_m1 Thermo Fisher Scientific 
Mrln Mm01175781_m1  Thermo Fisher Scientific 
MyHC Mm01332564_m1  Thermo Fisher Scientific 
Myogenin Mm00446194_m1 Thermo Fisher Scientific 
MyoD Mm00440387_m1 Thermo Fisher Scientific 
Pax3 Mm00435491_m1  Thermo Fisher Scientific 
Pax7 Mm01354484_m1 Thermo Fisher Scientific 
Ptch1 Mm00436026_m1 Thermo Fisher Scientific 
Smo Mm01162710_m1  Thermo Fisher Scientific 
Trim63 Mm01185221_m1  Thermo Fisher Scientific 
 
 
 
 
 
 
 
 
 
 52 
Results 
Modulation of the Hedgehog pathway altered myotube diameter and 
nuclear accretion 
 We first wanted to look at the regulation of the Hh pathway during 
myogenesis. To approach this question, we used murine C2C12 cells and 
collected total RNA at various time points throughout the differentiation process. 
We began with mononucleated myoblasts and differentiated them into 
multinucleated myotubes for four days (Figure 3-1A). Total RNA was collected 
from baseline myoblasts and at every 24 hours of differentiation. Consistent with 
what is known about the expression of myogenic regulatory factors during 
myogenesis, we saw a decrease in the expression of the satellite cell markers 
Pax3 and Pax7, and a robust increase in the expression levels of myogenin and 
myosin heavy chain. Analysis of mRNA expression levels of Ptch1 and Gli1 
showed that both were downregulated upon the onset of differentiation, and their 
expression decreased as it progressed (Figure 3-1B). As Ptch1 is a target gene 
for Gli1 transcriptional activity, these data would suggest that Hh pathway activity 
is decreased during C2C12 myogenesis 146-148. 
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Figure 3-1. Time course analysis of Ptch1 and Gli1 during differentiation. Total RNA was 
collected from myoblasts and differentiating myotubes every 24 hours. A: Representative images 
of C2C12 cells undergoing differentiation. B: Analysis of mRNA expression levels of Ptch1 and 
Gli1 shows they decreased as myoblasts began forming mature myotubes. All conditions were 
performed in triplicate and the data are expressed as the means  SD. Statistical significance 
was determined by one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 versus Day 1.  
 
 Next, we sought to investigate the in vitro effects of Hh pathway 
manipulation on C2C12 myotubes (Figure 3-2). For inhibitors of the pathway, we 
used the Smo inhibitors GDC-0449 and LDE225 and the Gli inhibitor GANT61. 
Activation of the pathway was done using Smoothened Agonist (SAG) 149. These 
inhibitors have been well characterized, with GDC-0449 and LDE225 being FDA-
approved 150,151.  
Day 1 Day 2 Day 3 Day 4 Day 5
A
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Figure 3-2. C2C12 model of treatment with Hh pathway agents. Graphical representation of 
the in vitro C2C12 model used to assess the phenotypic effects of Hh pathway modulation on 
myotubes. Myoblasts were differentiated into myotubes for four days before the designated 
treatment was added and incubated for an additional two. 
 
 We found that all the Hh pathway inhibitors used were able to induce 
significant myotube hypertrophy (Figure 3-3A-B). Conversely, treatment with 
SAG resulted in myotube atrophy (Figure 3-3C). In addition to the hypertrophic 
and atrophic effects, we also observed an alteration in nuclear accretion. 
Treatment with SAG caused a decrease in the number of nuclei per fiber, while 
use of the pathway antagonist GANT61 led to an increase in nuclei accumulation 
(Figure 3-3D). Taken together, these data suggest that Hh pathway activity can 
affect muscle fiber size, potentially through effects on myogenic differentiation. 
TreatmentDifferentiation
Day 1 Day 5:
drug 
addition
Day 7 analysis:
myotube
diameter, 
nuclei/fiber
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Figure 3-3. Modulation of the Hh pathway altered myogenesis. Myotubes were treated with 
an activator or inhibitors of the pathway before analysis of the myogenic phenotype. A: GDC-
0449 and LDE225 are inhibitors of Smo. SAG is a Smo agonist. GANT61 is a Gli inhibitor. B: 
Treatment with Hh pathway inhibitors GDC-0449, LDE225, and GANT61 resulted in larger 
myotubes. All conditions were performed in triplicate and the data are expressed as the means  
SEM. Statistical significance was determined by one-way ANOVA. *p<0.05, **p<0.01 versus 
Control. C: The addition of a pathway agonist to the culture media caused a reduction in myotube 
diameter. All conditions were performed in triplicate and the data are expressed as the means  
SEM. Statistical significance was determined by unpaired t test. *p<0.05 versus Control. D: The 
number of nuclei inside of the myotubes were counted for the various treatment conditions. An 
inhibitor of the Hh pathway increased the number of nuclei per fiber, while an activator decreased 
it. The same number of fibers were counted for each condition. All conditions were performed in 
triplicate and the data are expressed as the means  SEM. Statistical significance was 
determined by one-way ANOVA. *p<0.05 versus Control. 
C Control SAG 250nM
D Control SAG 250nM
GANT61 1μM
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A Hedgehog pathway agonist induced muscle wasting in vivo 
 Given the observed atrophy from treatment with a Hh pathway agonist in 
vitro, we next looked at whether these same effects could be seen in vivo. To test 
this hypothesis, eight week old male C57BL/6J mice were administered the Hh 
pathway agonist, Purmorphamine, via intraperitoneal injection once daily for 
seven days 152. Body weights were measured at baseline prior to the first dose 
and recorded every 24 hours over the course of the experiment. Mice treated 
with Purmorphamine lost a significant amount of weight when compared to the 
vehicle treated control group (Figure 3-4A). Analysis of body composition 
confirmed this, as Purmorphamine treatment resulted in a substantial loss in both 
total body lean and fat mass (Figure 3-4B). Mice in the vehicle treatment group 
showed no changes in total body lean mass and gained a significant amount of 
fat mass over the seven days. Analysis of individual skeletal muscles revealed a 
muscle wasting phenotype, similar to what we observed in vitro, and was 
consistent with the loss of total body weight and lean mass (Figure 3-4C). In 
addition, a drastic reduction in the epididymal fat pad mass was also observed. 
We do not believe that this atrophic muscle phenotype was a result of systemic 
organ wasting or toxicity as the heart and liver masses were not statistically 
different between the Purmorphamine and vehicle treated groups. These data 
suggest that in a non-disease state, activation of the Hh pathway results in 
skeletal muscle atrophy. 
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Figure 3-4. Systemic administration of a Hh pathway agonist resulted in skeletal muscle 
atrophy. Eight week old C57BL/6J mice were given Purmorphamine (n=6) or vehicle (n=6) once 
a day for seven days via intraperitoneal injection. Body weights were recorded daily and various 
muscles and organs collected at the time of necropsy. A: Purmorphamine treatment caused a 
significant reduction in body weight when compared to the vehicle control group. Changes are 
depicted as a percentage of the IBW measured at baseline (100%) prior to receiving the first 
dose. Data are expressed as the means  SD. Statistical significance was determined by two-way 
ANOVA. **p<0.01, ****p<0.0001 versus Control + Vehicle. B: Body composition analysis revealed 
that Purmorphamine treatment caused a significant loss of total body lean and fat mass. Vehicle 
treated control mice showed no change in total body lean mass and gained fat mass compared to 
their baseline measurements. Data are expressed as the means  SD. Statistical significance 
was determined by paired t test. **p<0.01, ****p<0.0001 versus Day 1. C: Various skeletal 
muscles and organs were compared between the groups. The values are normalized to the IBW 
of each individual animal in order to account for any difference in body size. Purmorphamine 
treated mice experienced atrophy in the gastrocnemius and tibialis anterior muscles, with a loss 
of epididymal fat pad mass as well. No wasting was observed in the heart or the liver. Data are 
expressed as the means  SD. Statistical significance was determined by unpaired t test 
**p<0.01, ***p<0.001 versus Control + Vehicle. 
 
Ptch1 knockdown resulted in impaired myogenesis 
 To further investigate the role of the Hh pathway in the maintenance of 
skeletal muscle, we next looked at the effects of Ptch1 knockdown on C2C12 
myogenesis (Figure 3-5). 
A
C
B
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Figure 3-5. Ptch1 knockdown. Graphical representation of Ptch1 knockdown in C2C12 
myoblasts. Myoblasts were transfected with either a Negative or Ptch1 siRNA. Knockdown cells 
were then cultured for 24 hours before qPCR analysis and validation of knockdown. The 
knockdown cells were then differentiated for four days prior to analysis of myotube diameter and 
nuclei per fiber. 
 
 Ptch1 functions as the endogenous inhibitor of the Hh pathway; thus 
knockdown of Ptch1 increased pathway activity, as evidence by the elevated 
expression of Gli1 (Figure 3-6A). After the initial 24 hours following transfection, 
the myoblasts were then differentiated for an additional four days before further 
analysis. We found that knockdown of Ptch1 resulted in significant decreases in 
both myotube diameter and the number of nuclei per myotube when compared to 
the Negative siRNA transfected controls (Figure 3-6B). Immunofluorescence 
staining for MyHC depicts the severely impaired differentiation of myoblasts 
knocked down for Ptch1 (Figure 3-6C). The myogenic deficiency observed was 
not due to toxicity from the transfection or cell death. Low magnification imaging 
shows the cells at full confluency in both experimental groups, indicating that the 
myoblasts knocked down for Ptch1 remained in a mononucleate state as 
opposed to entering terminal differentiation. These results suggest that increased 
Hh pathway activity, due to Ptch1 knockdown, significantly reduces the 
differentiation capacity of myoblasts. 
Differentiation24hrs
Transfection Day 1
analysis:
qPCR (Ptch1, 
Gli1)
Day 5 analysis:
myotube
diameter, 
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Figure 3-6. Increased Hh pathway activity led to defective differentiation. C2C12 myoblasts 
were knocked down for Ptch1 via siRNA. A: qPCR analysis confirmed Ptch1 knockdown and 
increased Hh pathway activity was confirmed by the upregulation of Gli1 expression. All 
conditions were performed in triplicate and the data are expressed as the means  SD. Statistical 
significance was determined by one-way ANOVA. ***p<0.001, ****p<0.0001 versus Control, 
###p<0.001, ####p<0.0001 versus Negative siRNA. B: Myoblasts knocked down for Ptch1 were 
differentiated into myotubes. Analysis of myotube diameter and nuclei per fiber shows that both 
were decreased when compared to the Negative siRNA transfected group. All conditions were 
performed in triplicate and the data are expressed as the means  SEM. Statistical significance 
was determined by unpaired t test. *p<0.05 versus Negative siRNA. C: Representative images of 
myotubes stained for MyHC and phase imagining. Ptch1 knockdown caused a severe impairment 
of differentiation. Phase imaging showed that this was not due to transfection toxicity or cell death 
as a result of the knockdown. 
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Hedgehog pathway activation results in a hypotrophic/atrophic muscle 
phenotype in mice 
 Because Ptch1 knockdown caused increased Hh pathway activity and 
impaired myogenesis in vitro, we next looked to model this scenario in vivo. 
Here, we assessed the skeletal muscle phenotype of Ptch1+/lacZ mice and WT 
littermates at various ages. With these transgenic mice, we would expect there to 
be increased Hh pathway activity due to Ptch1 haploinsufficiency. To test this, 
total RNA was extracted from tibialis anterior muscles and qPCR analysis 
performed. We found that in the Ptch1+/lacZ mice, Gli1 mRNA expression levels 
were upregulated when compared to WT littermates, indicating increased activity 
(Figure 3-7A). Concomitant with this increase in pathway activity, we observed a 
decrease in muscle mass in both 10 and 12 week old mice (Figure 3-7B). 
Analysis of muscle fiber cross-sectional area was consistent with the measured 
weights (Figure 3-7C). These findings are consistent with the prior in vitro and in 
vivo data, indicating that the Hh pathway acts as a negative regulator of adult 
skeletal muscle. 
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Figure 3-7. Ptch1 heterozygosity resulted in skeletal muscle atrophy. The skeletal muscle 
phenotype of Ptch1 heterozygous mice were compared to WT littermates. Mice were analyzed at 
6, 10, and 12 weeks of age. A: Functional loss of one Ptch1 allele resulted in increased Hh 
pathway activity, as evidenced by qPCR analysis of Gli1 mRNA expression levels. This was 
assessed in 6 week old Ptch1+/lacZ mice (n=7) and WT littermates (n=5), 10 week old Ptch1+/lacZ 
mice (n=9) and WT littermates (n=10), and 12 week old Ptch1+/lacZ mice (n=3) and WT littermates 
(n=5). Data are expressed as the means  SD. Statistical significance was determined by 
unpaired t test. **p<0.01, ***p<0.001, ****p<0.0001 versus WT. B: Weights of tibialis anterior 
muscles, normalized to TBW, were compared to WT littermates. Atrophy was observed at both 10 
and 12 weeks of age. Data are expressed as the means  SD. Statistical significance was 
determined by unpaired t test. *p<0.05, **p<0.01 versus WT. C: Representative images and 
quantification of tibialis anterior muscle fiber cross-sectional area. Data are expressed as the 
means  SD. Statistical significance was determined by unpaired t test. *p<0.05 versus WT. 
 
 We next sought to investigate a potential cause of the atrophic phenotype 
in the Ptch1+/lacZ mice. Western blotting analysis showed a significant decrease in 
the phosphorylation of substrates in the Akt pathway (Figure 3-8A). The Akt axis 
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is known to be a major pro anabolic pathway, and thus decreased Akt activity is 
consistent with our findings of smaller skeletal muscles 153. Conversely, looking 
at catabolic pathways, we found that the smaller muscle size was not 
accompanied by increased protein ubiquitylation (Figure 3-8B). Total protein 
ubiquitination was unchanged between Ptch1+/lacZ mice and WT littermates. In 
addition, mRNA expression levels of the E3 ubiquitin ligases Atrogin-1 and 
MuRF1 were comparable between the groups (Figure 3-8C). While these are 
indirect measurements of ubiquitin-mediated proteolytic degradation, they 
suggest no difference between groups. These data suggest that the skeletal 
muscle phenotype observed was caused by additional factors beyond Akt-
mediated protein synthesis and proteasome-mediated degradation. 
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Figure 3-8. Ptch1+/lacZ mice showed decreased activity of a pro anabolic pathway. Western 
blotting analysis of quadriceps muscle lysates from 10 week old Ptch1+/lacZ mice and WT 
littermates. A: Western blot image and quantification showed that phosphorylation of substrates 
in the Akt pathway were decreased in Ptch1 heterozygotes. Phosphorylation of Akt itself and total 
Akt levels were unchanged. Data are expressed at the means  SD. Statistical significance was 
determined by unpaired t test. **p<0.01 versus WT. B: Western blot image and quantification 
showed similar levels of total protein ubiquitination in Ptch1+/lacZ mice compared to WT littermates. 
Data are expressed as the means  SD. C: Total RNA was extracted from tibialis anterior 
muscles of 10 week old Ptch1+/lacZ mice and WT littermates. Expression levels of the E3 ubiquitin 
ligases Atrogin-1 and MuRF1 were comparable between the two groups. Data are expressed as 
the means  SD. 
 
Given that Hh pathway modulation in vitro with pharmacological agents 
altered nuclear accretion, we next looked to see if those effects were present in 
vivo as well. Analysis of skeletal muscle cross-sections showed a similar number 
of total nuclei between Ptch1+/lacZ mice and WT littermates. However, we found a 
significant decrease in the number of nuclei inside of the myofibers of Ptch1+/lacZ 
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mice, consistent with the findings from the in vitro SAG treatment (Figure 3-9A). 
The total number of fibers in the muscle were comparable between the groups. 
This suggests that the myofibers of Ptch1+/lacZ mice developed normally initially, 
but subsequently failed to acquire nuclei, rendering them smaller overall versus 
WT mice. To test the myogenic capacity of satellite cells in Ptch1+/lacZ and WT 
mice, primary myofibers were isolated from the FDB muscle and cultured in 
growth media for 24 hours prior to being stained for the satellite cell marker Pax7 
154,155. This protocol is known to activate proliferation of satellite cells associated 
with the myofiber. On a per fiber basis, Ptch1+/lacZ mice showed far fewer Pax7 
positive cells when compared to WT littermates (Figure 3-9B). Taken together, 
these data further suggest that the Hh pathway acts as a negative regulator of 
skeletal muscle mass by reducing myogenesis nuclear accretion. 
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Figure 3-9. Ptch1+/lacZ mice displayed aberrant, reduced myogenesis. Using the 10 week old 
mice, tibialis anterior cross-sections were assessed for nuclear accretion and FDB primary 
myofibers were isolated and analyzed for Pax7 expression. A: Representative images of cross-
sections of tibialis anterior muscles stained for dystrophin (green) and nuclei (blue). Analysis of 
the nuclei showed that both groups had a comparable number of total nuclei and the number of 
nuclei outside of myofibers. The red arrow and inset depict an example of a nuclei that was 
considered to be outside of a myofiber. However, Ptch1 heterozygotes had significantly less 
nuclei inside of the myofibers compared to WT littermates (white arrows). The yellow arrows and 
insets depict specific examples of what was considered to be inside of a myofiber. Data are 
expressed at the means  SD. Statistical significance was determined by unpaired t test. 
***p<0.001 versus WT. B: Primary myofibers were isolated from the FDB muscle and cultured for 
24 hours before being stained for Pax7. Representative images show Pax7+ cells (red) indicated 
by white arrows. Yellow arrows and insets show that the Pax7+ cells colocalized with nuclear 
staining (blue). Ptch1+/lacZ mice showed a significant decrease in the number of Pax7+ cells per 
myofiber. Data are expressed at the means  SD. Statistical significance was determined by 
unpaired t test. *p<0.05 versus WT. 
 
Ptch1+/lacZ mice showed differential regulation of genes associated with 
growth 
RNA sequencing was performed on the tibialis anterior muscles from 
Ptch1+/lacZ mice and WT littermates to evaluate differences in the transcriptome. 
Using Ingenuity Pathway Analysis, we found that a large number of the 
differentially regulated genes were involved in cell growth (Figure 3-10). In 
addition, Ptch1+/lacZ mice showed several folds downregulation of genes involved 
in cell proliferation and cell cycle. Western blotting analysis showed that the 
phosphorylation of cyclin-dependent kinases was less in Ptch1+/lacZ mice, 
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although this was not statistically significant (Supplemental Data). The 
downregulation of these genes could potentially explain the phenotype of smaller 
skeletal muscles. Analysis of muscle cross-sections showed a decrease in the 
number of nuclei that were inside of the myofibers, and cultured primary 
myofibers had far fewer Pax7 positive cells. The reduced expression of genes 
associated with cell cycle and growth could offer an explanation to this 
phenomenon. A decreased capacity for proliferation would mean a smaller pool 
of myoblasts and satellite cells. If these cells were less abundant, there would be 
fewer cells to differentiate and fuse into myofibers. 
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Figure 3-10. Differential regulation of genes associated with growth in Ptch1+/lacZ mice. 
Total RNA was extracted from the tibialis anterior muscles of 10 week old Ptch1+/lacZ mice (n=3) 
and WT littermates (n=3) and RNA-Seq analysis performed. RNA-Seq analysis showed 
decreased expression of several genes associated with cell proliferation and growth. Genes 
considered statistically significant had a p<0.05 and a false discovery rate (FDR) of less than 5%. 
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Ptch1+/lacZ mice exhibited a functional impairment of skeletal muscle 
 The atrophic skeletal muscles were not the only phenotype observed due 
to Ptch1 heterozygosity. We also observed a difference in muscle function 
between Ptch1+/lacZ mice and WT littermates. Four-limb grip strength test 
determines the peak force with which a mouse can hold on to a grid. The test 
was repeated three times for each mouse, with an opportunity to rest between 
each trial, and the recorded values were averaged. We first analyzed the mice at 
six weeks of age, and while we did observe a slight variation in grip strength, this 
was not statistically significant. However, when analyzed at 10 and 20 weeks of 
age, we observed a notable reduction in the strength of Ptch1+/lacZ mice (Figure 
3-11A). We then turned our attention to our RNA-Seq data in an attempt to find a 
possible explanation as to why these mice were so much weaker. These data 
provided evidence to suggest an alteration in calcium (Ca2+) handling and a 
decreased expression of genes encoding for myofibrillar structural proteins as a 
potential cause for the functional deficit. RNA-Seq data, confirmed by qPCR 
analysis, showed that Myoregulin (Mrln) was increased in Ptch1+/lacZ mice (Figure 
3-11B). Mrln functions to regulate Ca2+ uptake by interacting with the 
sarcoplasmic reticulum calcium transport ATPase (SERCA), and Mrln knockout 
mice have improved skeletal muscle performance 156,157. Furthermore, there was 
a downregulation of genes for several muscle structural proteins (Figure 3-11C). 
These genes included myomesin-3, -actinin-2, collagen type XV, and several 
myosin heavy chain isoforms. Taken together, these data support the 
observation that Ptch1+/lacZ mice were significantly weaker than WT littermates, 
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as irregular Ca2+ handling and a reduced expression of muscle structural proteins 
could greatly affect the contractility, function, and performance of skeletal 
muscle. 
 
 
Figure 3-11. Ptch1 heterozygosity resulted in a functional impairment of skeletal muscle. 
Four-limb grip strength was assessed in 6, 10, and 20 week old mice (20 week: Ptch1+/lacZ mice 
n=3, WT littermates n=3). A: Ptch1+/lacZ mice were significantly weaker when compared to WT 
littermates. This phenotype appeared to worsen with age. Data are expressed as the means  
SD. Statistical significance was determined by unpaired t test. *p<0.05, **p<0.01 versus WT. B: 
qPCR validation of Mrln expression from RNA extracted from the tibialis anterior muscles of 10 
week old Ptch1+/lacZ mice and WT littermates. Data are expressed as the means  SD. Statistical 
significance was determined by unpaired t test. **p<0.01 versus WT. C: RNA-Seq analysis 
showed decreased expression of genes encoding for skeletal muscle structural proteins. Genes 
considered statistically significant had a p<0.05 and an FDR<5%. Data are expressed as the fold 
change versus WT. 
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Discussion 
 Significant losses of skeletal muscle are extremely debilitating. This can 
occur from severe trauma or in degenerative diseases such as muscular 
dystrophy. Skeletal muscle atrophy is also a hallmark of many chronic diseases 
including cancer, AIDS, and organ failure. The Hh pathway plays a crucial role in 
embryonic skeletal muscle development 63,64,135,137. Several studies have been 
done looking at the pathways role in various injury and dystrophic muscle 
regeneration models 158-162. In these studies, exogenous overexpression of Shh 
is shown to be beneficial to the injury response. However, this upregulation of the 
Hh pathway is transient, and its benefits to regeneration may be explained by 
reverting the muscle to a more embryonic phenotype, which is known to occur 
163,164. The consequences of a prolonged and sustained elevation of Hh pathway 
activity, such as in a chronic disease state, have yet to be determined. As it 
stands, little has been done with regards to Hh in the maintenance of adult 
skeletal muscle. Here, we characterized the skeletal muscle phenotype of mice 
with elevated Hh pathway activity due to Ptch1 heterozygosity. In vitro, Hh 
pathway agonism resulted in myotube atrophy and a decreased number of nuclei 
per fiber. In vivo, systemic administration of Purmorphamine resulted in muscle 
wasting. A similar phenotype was observed in Ptch1+/lacZ mice, where Hh 
pathway activity is increased. Compared to WT littermates, Ptch1+/lacZ mice were 
significantly weaker, had smaller muscles, and showed reduced expression of 
genes associated with cell proliferation, cycle, and muscle structural proteins. 
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Together, these data support a role for the Hh pathway in maintaining normal 
adult skeletal muscle. 
 Our in vitro data suggests that the effects of Hh pathway modulation on 
myotube diameter is likely due to an alteration in the differentiation capacity of 
the myoblasts. Similar findings have previously been published by other groups. 
Lee et al. identified a small molecule inhibitor (SMI) that induces mouse 
embryonic stem cells to differentiate into muscle cells 165. The authors show that 
SMI2 is able to increase mRNA levels of several myogenic regulatory factors 
such as MyoD and Myogenin, as well as increasing the percentage of MyHC 
positive cells. They claim that one of the mechanisms responsible for this is the 
inhibition of Shh signaling. Moreover, co-treatment of SMI2 with a Smo agonist 
blunts the increases in myogenic genes induced by SMI2 treatment alone. 
Koleva et al. demonstrated that treatment of C2C12 myoblasts and primary 
satellite cells, with recombinant Shh, results in a complete inhibition of myotube 
formation 140. Additionally, the authors show that Shh causes a significant 
increase in BrdU incorporation, in a dose dependent fashion, in C2C12 
myoblasts and satellite cells. These data are consistent with our observations 
from SAG treatment resulting in a decreased number of nuclei per fiber, and 
Ptch1 knockdown leading to an impairment of C2C12 myogenesis. This suggests 
that increased Hh pathway activity inhibits myoblasts from arresting, entering 
terminal differentiation, and subsequently fusing 
 In vivo data from Purmorphamine treated and Ptch1+/lacZ mice sheds 
further light on the effects of increased Hh pathway activity on normal adult 
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skeletal muscle. As with the phenotype of smaller myotubes and impaired 
myogenesis that others and we have found in vitro, a similar observation was 
made in skeletal muscle tissue. It is well known that the Akt pathway plays a 
major role in the regulation of skeletal muscle both in vitro and in vivo 172-175. In 
vivo, it has been shown that transgenic mice with constitutive activation of Akt in 
the skeletal muscle exhibit remarkable hypertrophy 176. Conversely, Akt1 null 
mice are significantly smaller than both WT and heterozygous littermates 177. 
Though the authors do not specifically compare the skeletal muscles amongst 
the groups, null mice are 15-20% smaller throughout their lives. In a model of 
compensatory hypertrophy, Akt phosphorylation increases throughout the 
hypertrophy process 153. The study further demonstrates that Akt is also active 
during muscle hypertrophy in a model of recovery following disuse atrophy. 
Furthermore, electroporation of a constitutively active Akt plasmid results in 
significant hypertrophy, which is protective against muscle atrophy when used in 
a denervation injury model. Further analysis into the atrophic phenotype of 
Ptch1+/lacZ mice showed a decrease in the phosphorylation of substrates of the 
Akt pathway. Together those substrates include proteins that are involved in 
synthesis, proliferation, transcription, and anti-apoptotic proteins 166,167. Certain 
substrates of the pathway, such as GSK-3, have been shown to directly 
regulate skeletal muscle mass in both human and mouse 168-171. Reduced Akt 
activity thus may offer an explanation for the decrease in muscle mass that we 
observed in the Ptch1+/lacZ mice. 
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 In addition to having smaller muscles, the Ptch1+/lacZ mice also exhibited a 
functional deficit in skeletal muscle. Ptch1+/lacZ mice mice were much weaker than 
their WT littermates, and that this disparity was exacerbated with age. In the 
Ptch1+/lacZ mice, Mrln was significantly downregulated. Mrln encodes myoregulin, 
a micropeptide similar to sarcolipin and phospholamban which serve as key 
regulator of sarcoplasmic reticulum Ca2+ ATPases (SERCAs). In C2C12 
myoblasts, Mrln overexpression decreases Ca2+ levels in the sarcoplasmic 
reticulum, indicating that Mrln functions to inhibit the dynamics of the SERCA 
pump. When Mrln is deleted in the skeletal muscle, mice show a drastic increase 
in muscle performance. Compared to WT littermates, Mrln null mice ran 
approximately 30% longer when subjected to treadmill running until exhaustion 
exercise, which translates to a 55% increase in the total distance ran 156. The 
decreased expression of Mrln observed here could explain why the Ptch1+/lacZ 
mice were considerably weaker. 
 Another reason for the decrease in muscle strength in Ptch1+/lacZ mice 
could be attributed to the reduction in expression of genes encoding muscle 
structural proteins. In the Ptch1+/lacZ mice, genes encoding for several myosin 
heavy chain isoforms were downregulated, including both embryonic and adult 
fast myosins, likely affecting muscle function and myofibril stability 178,179. 
Additionally, Myomesin-3 expression levels were decreased 1.73 fold in the 
Ptch1+/lacZ mice. This protein is a component of the sarcomeric M-band, and 
plays a role in the network required for proper contraction of skeletal muscle 
180,181. Furthermore, -actinin-2 was downregulated 1.08 fold. This protein is 
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essential to the thin filaments of the muscle Z-disc 182-184. Our RNA-Seq data also 
showed a decrease in collagen type XV expression, by 1.09 fold. A knockout 
study of Col15a1 shows that null mice, while fertile and had normal gross 
development and lifespan compared to WT littermates, have several 
abnormalities in their skeletal muscle 185. At 13 weeks of age, histological 
analysis of the null mice shows signs of muscle degeneration. Furthermore, the 
Col15a1 knockouts were more vulnerable to exercise-induced muscle damage. 
Following bouts of heavy load treadmill running, Col15a1 knockout mice showed 
significantly increased -glucuronidase activity, a marker of damage, across 
several muscle groups. 
 Our data, both in vitro and in vivo, suggest that increased activation of the 
Hh pathway results in skeletal muscle atrophy. We believe that this is through a 
mechanism of impaired myogenesis based on the alterations in nuclear accretion 
that we observed. In addition, Ptch1 heterozygosity lead to a functional loss of 
muscle strength that we did not anticipate. While more work needs to be done to 
elucidate the exact mechanism for the myogenic deficiency, the data collected 
here indicate that the Hh pathway may act as a negative regulator of adult 
skeletal muscle homeostasis. Understanding the mechanism by which the Hh 
pathway regulates myogenesis will be crucial in determining the pathways 
therapeutic potential for diseases such as cancer cachexia or chronic illnesses 
that are known to be associated with skeletal muscle wasting. 
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Supplemental figures. Western blotting analysis of quadriceps muscle lysates from 10 week old 
Ptch1+/lacZ mice and WT littermates. Data are expressed as the means  SD. Statistical 
significance was determined by unpaired t test. **p<0.01. 
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Chapter 4 
Distinct roles of Gli1 and Gli2 in the molecular regulation of myogenesis 
 
Introduction 
 The Gli family of zinc-finger proteins, also known as glioma-associated 
oncogene, are transcription factors that regulate the downstream signal 
transduction cascade of the Hh family of ligands 186,187. In mammals, three 
members have been identified, Gli1, 2, and 3 188,189. While all three members 
share similarities, their ability to act as a transcriptional activator or repressor 
varies. All three Gli proteins possess the ability to act as a transcriptional 
activator 190,191. Gli1 has not been shown to have any repressor activity, instead 
functioning solely as a transcriptional activator. Gli2 serves as the primary 
transcriptional activator, although Gli3 does maintain this ability as well 192,193. 
Gli3 serves as the principal transcriptional repressor, with Gli2 also shown to 
have some repressor activity 194-196. Together, the Gli family of transcription 
factors function to mediate the transcriptional output of Hh signaling. 
 As discussed in the previous chapter, Shh signaling is crucial for the 
proper formation of skeletal muscle during development. How specific Gli 
proteins alter myogenesis and muscle development is incompletely understood. 
Prior studies in zebrafish indicate that the response to Hh signaling in myotomal 
cells is mediated by Gli1 and Gli2, with the two having partially overlapping 
functions 197. During mouse embryogenesis, the Gli proteins have been shown to 
have variable levels of expression. In epaxial muscle progenitor cells, Gli2 and 
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Gli3 have both been shown to have activating and repressive functions on Myf5 
transcription 198,199. However, the role of Gli proteins in the regulation of adult 
skeletal muscle myogenesis remains unclear. 
 Our prior in vitro and in vivo data has suggested that the Hh pathway acts 
as a negative regulator of adult skeletal muscle homeostasis. The observed 
effects appear to be through an alteration of myogenesis and differentiation. Here 
we sought to investigate molecular mechanisms. Gene expression studies during 
C2C12 myogenesis showed that Gli1 expression is downregulated upon 
induction of differentiation. In contrast, we found the opposite for Gli2. These 
proteins also have different functions, because Gli1 knockdown enhanced 
myogenic differentiation of C2C12 cells while Gli2 knockdown impaired 
differentiation.  Taken together, these data suggest that Gli1 and Gli2 have 
distinct and contrasting roles in myogenesis. 
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Materials and methods 
Cell cultures 
Murine C2C12 cells (ATCC) were grown in DMEM with 10% FBS, 100 
U/mL penicillin, and 100 mg/mL streptomycin, and maintained at low confluency 
at 37°C in a humidified atmosphere of 5% CO2. For differentiation of myoblasts, 
confluent cells were switched to a low serum medium containing DMEM 
supplemented with 2% horse serum, 100 U/mL penicillin, and 100 mg/mL 
streptomycin. SAG (Selleck Chemicals) was added to the differentiation media at 
a concentration of 250nM. 
For siRNA-mediated knockdown, commercially available siRNAs for Gli1, 
Gli2, and a negative control (Table 1) were transfected into C2C12 myoblasts 
using Lipofectamine 3000 as per the manufacturer’s instructions (Thermo Fisher 
Scientific). Knockdown of Gli1 and Gli2 in the myoblasts was confirmed via qPCR 
at 24 hours post transfection.  
For overexpression of GLI1, Ad-GLI1/GFP was made by cloning a full-
length cDNA of human GLI1 into a recombinant adenovirus serotype 5 construct 
co-expressing GFP from a separate promoter (Vector Biolabs). Ad-GLI1/GFP or 
Ad-GFP was added to the media of fully differentiated myotubes and analysis 
performed out to 60 hours post-infection. For knockdown of Gli2 in myotubes, an 
Ad-Gli2-shRNA was developed by cloning a Gli2 shRNA into an adenovirus 
serotype 5 backbone driven by a U6 promoter, with a separate GFP tag under a 
CMV promoter (Vector Biolabs). Ad-Gli2-shRNA or Ad-GFP was added to the 
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media of fully differentiated myotubes and incubated for 48 hours before analysis 
of myotube diameter was performed. 
Immunofluorescence 
 C2C12 myotubes were fixed and permeabilized in an ice cold 
acetone:methanol (1:1) solution for 20 minutes at -20°C. Cells were rehydrated 
with PBS at room temperature for 10 minutes, blocked in an 8% BSA solution for 
one hour, and primary antibody against MyHC (Developmental Studies 
Hybridoma Bank) incubated overnight at 4°C with gentle agitation. The following 
day, cultures were washed with PBS before being incubated with an AlexaFluor 
488-labeled anti-mouse IgG secondary antibody (Life Technologies) for one hour 
at room temperature and protected from light. Nuclei were stained with DAPI and 
images were captured on an Axio Observer.Z1 (Zeiss). Myotube diameters were 
measured using ImageJ analysis software (Wayne Rasband, U.S. National 
Institutes of Health). Only fully formed myotubes with the majority in the field of 
view were measured. MyHC expression was assessed by quantifying the total 
green fluorescence using the IncuCyte ZOOM platform and analysis software 
(Essen BioScience). 
Gene expression analysis 
 Total RNA was extracted from myoblasts and myotubes using the 
QIAGEN miRNeasy kit (QIAGEN Inc.) and cDNA generated using the Verso 
cDNA Synthesis kit (Thermo Fisher Scientific) as per the manufacturer’s 
instructions. Relative mRNA expression levels were measured using TaqMan 
Assay based probes (Thermo Fisher Scientific) on a LightCycler 96 (Roche). A 
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complete list of the probes used in these experiments can be found on Table 4-1 
below. 
Data analysis 
Statistical significance was determined by unpaired t-test for experiments 
containing two groups. For experiments containing groups of three or more, 
statistical significance was determined by one-way ANOVA and Tukey’s multiple 
comparisons test. A p-value less than 0.05 was considered to be statistically 
significant. 
Table 4-1. 
siRNA   
Target Catalog # Manufacturer 
Negative 4390846 Thermo Fisher Scientific 
Gli1 - A s66723  Thermo Fisher Scientific 
Gli1 - B s66724  Thermo Fisher Scientific 
Gli2 s66726  Thermo Fisher Scientific 
   
Probes   
Target Catalog # Manufacturer 
Gli1 Mm00494654_m1  Thermo Fisher Scientific 
Gli2 Mm01293117_m1  Thermo Fisher Scientific 
Gli3 Mm00492337_m1  Thermo Fisher Scientific 
MyoD Mm00440387_m1  Thermo Fisher Scientific 
Myogenin Mm00446194_m1  Thermo Fisher Scientific 
Pax7 Mm01354484_m1  Thermo Fisher Scientific 
Ptch1 Mm00436026_m1 Thermo Fisher Scientific 
 
 
 
 
 
 85 
Results 
Gli1 and Gli2 are inversely regulated during myogenesis 
 We previously showed that Gli1 expression was downregulated during 
C2C12 myogenesis. Upon further analysis of this experiment, Gli2 was found to 
be highly upregulated at the onset of differentiation, and remained so throughout 
the differentiation process (Figure 4-1A-B). This suggested that Gli1 and Gli2 
may have specific non-redundant functions in the regulation of myogenesis. 
 
Figure 4-1. Gli1 was downregulated during differentiation, while Gli2 was upregulated. 
Analysis of Gli1 and Gli2 mRNA expression levels during C2C12 myogenesis. A: Representation 
images of C2C12 myoblasts differentiating into C2C12 myotubes. B: Gli1 expression became 
downregulated during differentiation and Gli1 expression increased. All conditions were 
performed in triplicate and the data are expressed as the means  SD. Statistical significance 
was determined by one-way ANOVA. ****p<0.0001 versus Day 1. 
 
Upregulation of Gli1 halted differentiation 
 Given that Gli1 was downregulated during C2C12 myogenesis, we next 
sought to determine what the effects of Gli1 upregulation would be on it. Here, 
we treated differentiated myotubes with SAG, and assessed the myogenic 
phenotype. The addition of SAG resulted in a significant upregulation of Gli1 at 
both 24 and 48 hours after treatment (Figure 4-2). 
Day 1 Day 2 Day 3 Day 4 Day 5
A
B
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Figure 4-2. SAG induced Gli1 expression. Differentiating myotubes were incubated with SAG 
for 48 hours and Gli1 mRNA levels were analyzed at 24 hour intervals after treatment began. All 
conditions were performed in triplicate and the data are expressed as the means  SD. Statistical 
significance was determined by unpaired t test. ****p<0.0001 versus Control. 
 
 We next observed that increased Gli1 expression appeared to have 
stopped the progression of differentiation. We assessed the changes in myotube 
diameter, total nuclei, and the number of nuclei per fiber from differentiating 
myotubes treated with SAG for 24 and 48 hours (Figure 4-3). 
 
Figure 4-3. SAG treatment of differentiating C2C12 myotubes. C2C12 cells were 
differentiated for four days before treatment with either vehicle or SAG. Following treatment, 
myotubes were analyzed for diameter, total nuclei, and nuclei per fiber at 24 (Day 6) and 48 
hours (Day 7). 
 
When analyzing the vehicle treated controls from 24 to 48 hours post-treatment, 
we found that these cells continued to differentiate and fuse, as evidenced by the 
increase in myotube diameter. However, when looking at the cells treated with 
TreatmentDifferentiation
Day 1 Day 5:
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Day 7 
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myotube
diameter, 
nuclei/fiber
Day 6 
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myotube
diameter, 
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SAG from 24 to 48 hours post-treatment, we found that differentiation had 
ceased. With SAG treatment, the myotube diameter did not continue to increase 
as it did in the controls, and no further nuclei were accumulated (Figure 4-4A-C). 
In addition, the total number of nuclei in the SAG treated group showed an 
upward trend from 24 to 48 hours after treatment, indicating that there was no 
toxicity or cell death. Taken together, these data suggest that increased 
expression of Gli1 halts differentiation and may maintain myoblasts in a 
mononucleated state. 
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Figure 4-4. Increased Gli1 expression blocks differentiation. Myotubes with increased Gli1 
expression were unable to continue undergoing differentiation and myoblast fusion. A: 
Representative images of Control and SAG treated myotubes 24 hours after incubation. B: 
Representative images of Control and SAG treated myotubes 48 hours after incubation. C: 
Analysis of myotube diameter, total nuclei, and nuclei per fiber. Control myotubes showed an 
increase in diameter from 24 to 48 hours following vehicle treatment, and a trend for more nuclei 
per fiber. SAG treated myotubes did not continue to grow or accrue more nuclei based on the 
analysis from 24 to 48 hours. All conditions were performed in triplicate and the data are 
expressed as the means  SEM. Statistical significance was determined by unpaired t test. 
**p<0.01 versus 24 hours. 
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Gli1 knockdown enhanced myogenesis, Gli2 knockdown impaired 
 We next questioned what the effects on myogenesis would be from 
knocking down Gli1 and Gli2. Based on our previous data, we hypothesized that 
knocking down Gli1 would be beneficial due to the fact that it is downregulated 
during C2C12 myogenesis, and inducing its expression halted myogenesis. 
Conversely, since Gli2 is upregulated during myogenesis, knocking it down 
would likely be detrimental. To investigate this hypothesis, we transfected C2C12 
myoblasts with an siRNA targeting Gli1, Gli2, or a negative control (Figure 4-5A). 
After an initial 24 hours following siRNA knockdown, qPCR analysis was 
performed to confirm a decreased expression of Gli1 and Gli2 (Figure 4-5B). 
With their downregulation confirmed, these knockdown myoblasts were then 
differentiated into myotubes and the phenotype assessed. When looking at 
differentiation as a whole, it was evident that the myoblasts knocked down for 
Gli1 formed significantly more myotubes than the Negative siRNA transfected 
myoblasts. On the other hand, the Gli2 knockdown myoblasts showed very few 
myotubes after four days of differentiation (Figure 4-5C). The lack of 
differentiation observed was not due to toxicity from the transfection or cell death 
resulting from the knockdown, as phase imaging shows nearly full confluency in 
all the groups. Upon further analysis, we found that MyHC expression was 
significantly increased in the myotubes generated from Gli1 knockdown 
myoblasts compared to the Negative siRNA, indicating an enhancement of 
differentiation. In the myotubes generated from Gli2 knockdown myoblasts, 
MyHC expression was decreased, consistent with the observation of a severe 
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impairment of differentiation (Figure 4-5D). Additionally, the myotubes generated 
from Gli2 knockdown myoblasts showed a decrease in the number of nuclei per 
fiber and a trend towards smaller myotube diameters, further supporting the 
phenotype of defective myogenesis. 
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Figure 4-5. Gli1 and Gli2 knockdown resulted in enhanced and impaired myogenesis, 
respectively. The myogenic phenotype of myotubes, differentiated from C2C12 myoblasts 
knocked down for Gli1 or Gli2, was assessed A: C2C12 myoblasts were knocked down for either 
Gli1 or Gli2. Following 24 hours in culture, the myoblasts were then analyzed to confirm 
knockdown before being differentiated to myotubes. B: qPCR analysis of Gli1 and Gli2 mRNA 
expression levels in myoblasts 24 hours post-transfection. All conditions were performed in 
triplicate and the data are expressed as the means  SD. Statistical significance was determined 
by unpaired t test. ****p<0.0001 versus Negative siRNA. C: Representative images of myotubes 
stained for MyHC and phase imagining. Gli1 knockdown increased differentiation, while Gli2 
knockdown reduced. D: Myoblasts knocked down for Gli1 or Gli2 were differentiated into 
myotubes. Gli1 knockdown resulted in increased MyHC expression. Gli2 knockdown resulted in 
decreased expression of MyHC and a reduced number of nuclei per fiber. All conditions were 
performed in triplicate and the data are expressed as the means  SD. Statistical significance 
was determined by one-way ANOVA. **p<0.01, ***p<0.001, ****p<0.0001 versus Negative siRNA. 
 
Gli2 knockdown resulted in a decreased expression of myogenic genes 
 Next, we sought to investigate what a potential mechanism for the 
myogenic deficit of the Gli2 knockdown myoblasts could be. Total RNA was 
extracted from Gli2 knockdown myoblasts cells at baseline (Day 1) and every 24 
hours as differentiation progressed. We then analyzed the mRNA expression 
levels of Gli family members and various myogenic regulatory factors. Gli2 was 
found to be decreased at every time point in the experiment, confirming 
knockdown, while Gli1 expression was comparable to control levels of the 
Negative siRNA transfected group. This suggests that Gli1 and Gli2 work 
independently of each other during differentiation. When looking at myogenic 
regulatory factors, two of the essential genes necessary for myogenesis, MyoD 
and Myogenin, were both significantly downregulated at every time point in the 
Gli2 knockdown group (Figure 4-6). Furthermore, the satellite cell marker Pax7 
D
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became upregulated while the cells underwent differentiation. Together, these 
data suggest that the impaired myogenesis observed in the Gli2 knockdown cells 
is due to a reduced expression of genes associated with entry and progression 
through myogenesis, and an increased expression of a progenitor cell marker. 
 
Figure 4-6. Gli2 knockdown resulted in a reduced expression of myogenic regulatory 
factors. Time course analysis of gene expression in Gli2 knockdown cells undergoing 
differentiation. The muscle specific genes MyoD and Myogenin were decreased with Gli2 
knockdown and Pax7 was increased. All conditions were performed in triplicate and the data are 
expressed as the means  SD. Statistical significance was determined by one-way ANOVA. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 versus Negative siRNA. 
 
GLI1 overexpression caused dedifferentiation of myotubes, Gli2 
knockdown caused atrophy 
 Thus far, our data looking at the myogenic effects of Gli1 and Gli2 
manipulation have been performed in myoblasts. We next looked to investigate 
the effects of these factors being perturbed in fully differentiated myotubes. When 
GLI1 was overexpressed in myotubes, we observed a phenotype of 
dedifferentiation. This was accompanied by a loss of MyHC staining that 
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progressed over time and resulted in significantly smaller myotubes (Figure 4-7). 
Nuclear staining showed that this was not due to toxicity or cell death. 
 
Figure 4-7. Overexpression of GLI1 resulted in myotube dedifferentiation. Differentiated 
C2C12 myotubes were infected with either Ad-GFP or Ad-GLI/GFP. Staining for MyHC (red) at 
various time points showed that overexpression of GLI1 resulted in a loss of MyHC in myotubes. 
Nuclei staining (blue) at the 60 hour time point showed that this was not due to cell death. 
Analysis of myotube diameters at 60 hours post-infection showed a significant reduction in the 
myotubes infected with Ad-GLI1/GFP. All conditions were performed in triplicate and the data are 
expressed as the means  SD. Statistical significance was determined by unpaired t test. 
***p<0.001 versus Ad-GFP. These data were collected by a former graduate student, Rui Zhan. 
 
 Next, we looked at what the effects of knocking down Gli2 in differentiated 
myotubes would be. Infection with a Gli2 Ad-shRNA resulted in significant 
myotube atrophy (Figure 4-8A-B). This is consistent with our prior observation 
that knockdown of Gli2 in myoblasts impaired differentiation. Analysis of mRNA 
expression levels showed that Gli2 was significantly decreased in the myotubes 
infection with the Gli2 Ad-shRNA (Figure 4-8B). Taken together, these data 
further suggest that Gli1 functions to maintain cells in a proliferative state, while 
Gli2 functions to allow for terminal differentiation and the expression of muscle 
specific genes. 
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Figure 4-8. Knockdown of Gli2 in myotubes resulted in fiber atrophy. C2C12 myotubes were 
infected with an adenovirus expressing either Scrambled shRNA with a GFP tag or a Gli2 shRNA 
with a GFP tag. A: Representative images of myotubes infected with 3.3x1010 PFU/mL of 
Scrambled shRNA, 1.4x1010 PFU/mL of Gli2 Ad-shRNA, or 2.8x1010 PFU/mL of Gli2 Ad-shRNA. 
B: qPCR analysis showed that infection of the myotubes with the adenovirus significantly reduced 
Gli2 mRNA expression levels. Measurement of myotube diameters revealed that the reduction of 
Gli2 expression caused a decrease in myotube size. All conditions were performed in triplicate 
and the data are expressed as the means  SD. Statistical significance was determined by one-
way ANOVA. *p<0.05, ***p<0.001, ****p<0.0001 versus Scrambled shRNA. 
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B
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Discussion 
 Our previous in vitro and in vivo data have shown that the Hh pathway 
acts as a negative regulator of skeletal muscle mass, with further evidence 
suggesting this to be through a modulation of myogenic potential. In an attempt 
to further explore the mechanism by which the Hh pathway regulates muscle 
mass, we looked at Gli1 and Gli2 and their role in myogenesis. During C2C12 
myogenesis, Gli1 is downregulated while Gli2 is upregulated, indicating that 
these two factors may have distinct roles during this process (Figure 4-9). 
Looking further into Gli1, we found that when its expression was induced, 
myogenesis was halted. When Gli1 was knocked down in myoblasts, these cells 
had a much higher capacity to differentiate, as evidenced by an increase in 
MyHC expression. Overexpression of Gli1 in myotubes provided further evidence 
that it functions to keep muscle progenitor cells in an undifferentiated state, as 
the myotubes dedifferentiated. Conversely, knockdown of Gli2 resulted in a 
severely reduced capability of myoblasts to form multinucleated myotubes. This 
was likely due to a reduced expression of key myogenic regulatory factors, and a 
sustained and elevated expression of a muscle satellite cell marker. When Gli2 
was knocked down in mature myotubes, they atrophied. These findings suggest 
that Gli2 is necessary to both initiate and maintain the differentiated state. 
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Figure 4-9: Gli1 and Gli2 had non-redundant roles during myogenesis. Our data suggest a 
model in which Gli1 and Gli1 have unique roles on the molecular regulation of myogenesis. 
Knockdown of Gli1 in myoblasts resulted in enhanced myogenesis, while GLI1 overexpression in 
myotubes caused dedifferentiation. Gli2 knockdown in myoblasts severely impaired myogenesis, 
while knockdown in myotubes resulted in atrophy. 
 
 The role of Gli1 and Gli2 in myogenesis has been investigated in the 
literature, although there is no consensus as to whether they are permissive or 
inhibitory to myogenesis. Several studies performed using pluripotent P19 cells 
suggest that the Gli proteins are essential to the expression of key myogenic 
regulatory factors. Arsenic is a toxicant that has been shown to suppress 
myotube formation in C2C12 cells 200. When used in P19 cells, exposure to 
arsenic reduces Gli2 expression both at the mRNA and protein level 201. 
Moreover, overexpression of Gli2 is sufficient to induce myogenesis in P19 cells, 
without the presence of a differentiation inducing agent. This results in 
expression of MyHC and detection of Myf5 and Myogenin transcripts, which were 
not observed in control P19 cells. Conversely, when the activation domain of Gli2 
was replaced with an engrailed repression domain, P19 cells expressing this 
form of Gli2 did not differentiate into myocytes or express Myf5 202. A similar 
study was done that confirmed these findings. Again, Gli2 overexpression was 
shown to enhance skeletal muscle cell formation in P19 cells, accompanied by 
Gli2 knockdown in myoblasts: impaired myogenesis Gli2 knockdown in myotubes: atrophy
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an increase in the expression of MEF2C, MyoD, Myf5, and Myogenin. This study 
goes on to show that Gli2 directly interacts with MEF2C and MyoD to form a 
protein complex, thus enhancing the activity of MyoD 203. However, it has also 
been shown that Gli1 and Gli2 are inhibitory to MyoD activity. Using several 
MyoD-responsive reporters, one study shows that transfection with either a Gli1 
or Gli2 expression plasmid severely reduces the expression of the reporters 204. 
This would suggest that Gli1 and Gli2 block myogenesis by inhibiting the 
necessary transcriptional activity of MyoD. 
 Here, we show that Gli1 and Gli2 have unique and non-redundant roles 
during myogenesis. The published literature showing that Gli1 inhibits MyoD 
activity would offer a potential explanation as to why we saw an increase in 
differentiation and myotube formation with Gli1 knockdown. Although, their 
finding that Gli2 also blocks MyoD activity is not in agreement with ours or other 
published data. We found that with Gli2 knockdown, differentiation was almost 
completely ablated, and the expression of various myogenic regulatory factors 
was decreased. This seems to be due to the fact that Gli2 forms a protein 
complex with MyoD in order to enhance its activity, as shown by Voronova et al.. 
Taken together, our data suggest the Hh pathway as a potential target for 
therapeutic intervention of muscle wasting diseases, but Gli1 and Gli2 have 
distinct roles during myogenesis and must be targeted accordingly.  
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Chapter 5 
Conclusions 
 
Skeletal muscle plays an important role in human health and disease. The 
loss of skeletal muscle can have devastating consequences on a patient’s quality 
of life, response to treatment, or survival. There is an overwhelming need to 
identify and investigate new targets for therapeutic intervention to treat these 
patients.  
Here, we investigated ERK inhibition as a treatment to prevent cancer-
induced cachexia. The effects on lean body mass in the phase II clinical trial 
using Selumetinib, and the published literature on ERK inhibition in the skeletal 
muscle, lead us to hypothesize that ERK inhibition with Selumetinib might be 
effective at blocking cancer-associated muscle wasting. In vitro, we found that 
Selumetinib was able to induce C2C12 myotube hypertrophy and nuclear 
accretion. In an in vivo mouse model of experimental cancer cachexia, however, 
Selumetinib reduced tumor mass, circulating and tumor levels of IL-6, but did not 
preserve muscle mass. Similar wasting was seen in limb muscles of Selumetinib 
and vehicle treated LLC tumor bearing mice, while greater fat loss was observed 
in the Selumetinib treated group. Additionally, Selumetinib did not block wasting 
in C2C12 myotubes treated with plasma from LLC tumor mice. Taken together, 
our results suggest that this inhibitor was not protective in LLC cancer cachexia 
despite the reduction in IL-6 levels and tumor mass, and may have actually 
exacerbated tumor-induced wasting. 
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While positive effects on the tumor were observed, we did not find there to 
be any reductions in weight loss or muscle wasting with Selumetinib treatment. 
The data point to the fact that careful consideration must be taken when 
extrapolating results from clinical trials and applying across different experimental 
models and disease states. Studies must take into account the potential for 
differential regulation on pathways in commonly used models of cancer cachexia, 
and a diversity in the underlying molecular mechanisms. These data do however 
warrant further investigation into the efficacy of MEK inhibition as a treatment for 
cancer-induced cachexia. As previously mentioned, ERK1/2 activation is required 
during different stages of differentiation. Thus, it would seem that constant 
inhibition of the pathway would actually have a negative effect on muscle mass. 
While it is not likely that we would be able to modulate a certain stage of 
differentiation in vivo with Selumetinib, an alternative method would be to use a 
cyclic dosing regimen. This would allow for periods of inhibition, which would be 
beneficial during the initial stages of differentiation, as well as periods of 
activation, which is necessary in the later stages. Coupled with the positive 
effects observed on tumor mass, if future studies can elucidate a more beneficial 
dose for skeletal muscle hypertrophy, ERK inhibition may be a viable option to 
combat cancer cachexia. 
The data obtained in this study also suggest that there are additional 
cachectic drivers at play in this model. While a decrease in the tumor and 
circulating levels of IL-6 were observed in vivo, Selumetinib was unable to protect 
against LLC plasma induced myotube wasting in vitro. This result could be due to 
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another, or several other, cachectic mediators that are still present at high levels. 
Future studies may look to identify what additional factors are elevated such as 
TNF, Activins, or members of the TGF- family. Once identified, a combination 
therapy approach, targeting the factor(s) in conjunction with Selumetinib, may 
provide a protective effect against muscle wasting by inhibiting the production of 
multiple cachectic drivers. 
Our lab also has substantial data implicating the Shh pathway as a causal 
factor in skeletal muscle wasting. Prior work has found the pathway to be 
activated in the skeletal muscles of LLC tumor bearing mice. Moreover, inhibition 
of the Shh pathway in LLC tumor bearing mice was able to protect against 
cancer-induced cachexia, while having no effect on tumor mass. This brought 
about the question of how the Hh pathway regulates normal adult skeletal muscle 
mass. 
Looking in vitro, we found that pharmacological inhibition or activation of 
the Hh pathway resulted in C2C12 myotube hypertrophy and atrophy, 
respectively. In addition, we also observed an alteration in the nuclear accretion 
of these myotubes, with inhibition of the pathway increasing and activation 
decreasing. Further in vitro worked showed that when Ptch1 was knocked down, 
resulting in increased Hh pathway activity, C2C12 differentiation was severely 
impaired. Prior data from the lab showed that in vivo inhibition of the Hh pathway 
resulted in systemic muscle hypertrophy. Here, we showed that the use of a 
pathway agonist caused systemic skeletal muscle and adipose tissue wasting. 
Using a transgenic model of increased Hh pathway activity, we found that mice 
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heterozygous for Ptch1 had smaller muscles and were significantly weaker. 
Further analysis of the muscle phenotype revealed that this was likely due to a 
defect in myogenesis, as we observed fewer nuclei inside of the muscle fibers 
and less Pax7+ cells on isolated primary myofibers. RNA-seq analysis showed a 
reduction of genes associated with cell cycle and proliferation and muscle 
structural proteins, offering an explanation to the reduced myogenic phenotype 
and muscle strength. Together, these data further supported our hypothesis that 
the Hh pathway acts as a negative regulator of adult skeletal mass. 
 Lastly, we wanted to look more into the molecular regulation of 
myogenesis by the Hh pathway, specifically the roles of the Gli1 and Gli2 
transcription factors. We found that during normal C2C12 myogenesis, these 
factors were differentially regulated, as Gli1 expression decreased as 
differentiation progressed, and Gli2 expression increased. When Gli1 expression 
was induced, differentiation was arrested, as the myotubes no longer accrued 
additional nuclei or increased in diameter. In addition, when Gli1 was knocked 
down in myoblasts, these cells had an increased capacity to differentiate and 
form multinucleated myotubes. Furthermore, when GLI1 was overexpressed in 
fully differentiated myotubes, we observed a dedifferentiation phenotype. 
Together, these data suggest that Gli1 functions to keep myoblasts in a 
proliferative state. When Gli2 was knocked down in myoblasts, we observed a 
severe impairment of differentiation. This was accompanied by a decreased 
expression of the muscle specific genes MyoD and Myogenin. Moreover, when 
Gli2 was knocked down in mature myotubes, we observed an atrophic effect, 
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suggesting that Gli2 functions to maintain the differentiated state of myotubes. 
Our data indicate that Gli1 and Gli2 serve two distinct roles during myogenesis, 
with Gli1 functioning in myoblasts to maintain their mononucleated state, and 
Gli2 the differentiated phenotype. 
 In order to further elucidate the role of Gli1 and Gli2 in myogenesis, future 
studies will need to be performed both in vitro and in vivo. In vitro, it will be 
interesting to look at whether the cells that dedifferentiate, due to GLI1 
overexpression, can then be induced to differentiate again into myotubes. This 
may offer clues as to whether the increased expression of GLI1 resulted in a 
change in the gene profile to a more proliferative state, as our other data would 
suggest, or if it further transformed the cells into a different lineage or cell type. In 
vivo, future studies would look to confirm the in vitro findings with Gli1 and Gli2 
manipulation. We would look to characterize the skeletal muscle phenotype of 
mice that were overexpressing or knocked out for Gli1 or Gli2 specifically in the 
skeletal muscle. This could be accomplished either by the use of transgenic 
mouse models, or through a targeted local approach of intramuscular injections 
with plasmids or RNA interference. These studies would help to further validate 
the results obtained here. 
 The data shown here present two pathways that warrant further 
investigation as potential therapeutic targets for the treatment of muscle wasting 
diseases. ERK inhibition showed positive effects on tumor volume, but not the 
desired protection of skeletal muscle mass. Future experiments may be able to 
resolve this with changes to the dosing regimen, either concentration or the 
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frequency of administration. The lab has produced substantial evidence that 
points to the Hh pathway as a negative regulator of skeletal muscle mass. 
Inhibition of this pathway was shown to induce hypertrophy, while activation 
induced wasting. Targeting the pathway may prove to be beneficial in disease 
where muscle wasting is prevalent. However, the data here suggest that the 
downstream Gli1 and Gli2 transcription factors have unique and opposing roles 
during myogenesis. This indicates that caution must be taken as to which factors 
are inhibited if the pathway is to be targeted. With the overall goal of biomedical 
research to improve patient outcomes, survival, and quality of life, it is essential 
to continually investigate pathways and identify new targets for therapeutic 
intervention. 
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